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Abstract
Cryptosporidium parvum is an enteric protozoan parasite that has emerged as a major cause of
diarrhea, malnutrition and gastroenteritis as well as posing a potential bioterrorism threat. C.
parvum synthesizes guanine nucleotides from host adenosine in a streamlined pathway that relies
on inosine 5′-monophosphate dehydrogenase (IMPDH). We have previously identified several
parasite-selective C. parvum IMPDH (CpIMPDH) inhibitors by high-throughput screening. In this
paper, we report the structure-activity relationship (SAR) for a series of benzoxazole derivatives
with many compounds demonstrating CpIMPDH IC50 values in the nanomolar range and > 500-
fold selectivity over human IMPDH (hIMPDH). Unlike previously reported CpIMPDH inhibitors,
these compounds are competitive inhibitors versus NAD+. The SAR study reveals that pyridine
and other small heteroaromatic substituents are required at the 2-position of the benzoxazole for
potent inhibitory activity. In addition, several other SAR conclusions are highlighted with regard
to the benzoxazole and the amide portion of the inhibitor, including preferred stereochemistry. An
x-ray crystal structure of a representative E•IMP•inhibitor complex is also presented. Overall, the
secondary amine derivative 15a (Q67) demonstrated excellent CpIMPDH inhibitory activity (IC50
= 0.5 ± 0.1 nM) and moderate stability (t1/2 = 44 min) in mouse liver microsomes. Compound 73,
the racemic version of 15a, also displayed superb antiparasitic activity in a Toxoplasma gondii
strain that relies on CpIMPDH (EC50 = 20 ± 20 nM), and selectivity versus a wild-type T. gondii
strain (200-fold). No toxicity was observed (LD50 > 50 μM) against a panel of four mammalian
cells lines.
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Introduction
Cryptosporidiosis is an intestinal diarrheal disease most commonly caused by
Cryptosporidium parvum and hominis. These protozoan parasites are widely distributed in
both the developing and developed worlds1 and a major cause of severe diarrhea and
malnutrition in children2. Infection is self-limiting in immune-competent adults, but chronic
in immunocompromised individuals and children. Infections are transmitted by the fecal to
oral route through drinking and recreational waters3. The infectious oocysts are resistant to
standard water treatment methods like bleach and filtration. C. parvum oocysts are readily
obtained from infected calves, and could potentially be used as a bio-weapon 4. Hence, C.
parvum is categorized as a class B bio-warfare agent. Furthermore, currently available drugs
are not effective for treating cryptosporidiosis and vaccine therapy is lacking5, so new drugs
are needed.
Cryptosporidium are intracellular parasites. Genomic analysis revealed that these parasites
cannot synthesize purine nucleotides de novo, but instead salvage adenosine from the host6.
Adenosine is converted into guanine nucleotides in a streamlined pathway that relies on
inosine 5′-monophosphate dehydrogenase (IMPDH) catalyzing the conversion of inosine
5′-monophosphate (IMP) to xanthosine 5′-monophosphate (XMP) 7. The parasite enzyme
(CpIMPDH) is structurally distinct from mammalian IMPDHs. Cryptosporidium appears to
have obtained its IMPDH gene from bacteria via lateral gene transfer6b, 6c, 8. Therefore,
CpIMPDH has emerged as an attractive molecular target for the development of effective
therapeutics for the treatment of diseases associated with this recalcitrant organism.
As previously reported, a high throughput screening campaign identified structurally diverse
selective CpIMPDH inhibitors9. Several of these compound series have been optimized to
produce low nanomolar CpIMPDH inhibitors such as A110, C64, C97, P96 and D48
(Figure 1)10. Herein, we report the structure-activity relationship for the benzoxazole-based
inhibitor 1, a co-crystal structure of a representative derivative of this compound series with
CpIMPDH and anti-parasitic activity for a subset of compounds in a Toxoplasma gondii
surrogate model.
Results and Discussion
Chemistry
Various derivatives of 1 were synthesized using the methods depicted in Scheme 1. 5-
Nitro-2-arylbenzoxazoles 3 were prepared from 2-amino-4-nitrophenols 2 and aromatic
aldehydes in the presence of activated carbon (DarcoKB)11. Reductive hydrogenation of 3 in
the presence of 10% Pd-C provided 5-amine-2-arylbenzoxazoles 4. Substituted phenols and
anilines were converted to the corresponding ethers and amines 6 upon treatment with ethyl
2-bromopropionates in the presence of K2CO3. Enantiomerically pure phenyl ethers were
synthesized by using Mitsunobu reaction conditions with (+)-methyl D-lactate or (-)-methyl
L-lactate10a. Ester hydrolysis was carried out in THF with 3M sodium hydroxide for
racemic esters and with 3N HCl in THF for enantiomerically pure esters to yield acids 7.
Subsequently, 7 was coupled with 5-amine-2-arylbenzoxazoles 4 with the aid of EDCI•HCl
in anhydrous DMF yielding amides 8. N-alkylation of the amide was carried using sodium
hydride and iodomethane to give 9 in moderate yield.
Enantiomerically pure benzoxazole amines were prepared using the method outlined in
Scheme 2. L-alanine (10) was allowed to react with 2,3-di-chloroiodobenzene in the
presence of CuI and Cs2CO3 to give 11 12. The acid was coupled with a benzoxazole amine
derivative with the aid of EDCI•HCl to give 15a. Copper (II) acetate mediated coupling of
L-alanine methyl ester with 1-naphthyl boronic acid (12) yielded 1313. Hydrolysis under
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mild basic conditions generated acid 14, which was subsequently coupled with a 5-amine-2-
(4-pyridyl)benoxazole to yield 15b.
An analogue of 1 lacking the ether oxygen was prepared following the synthetic procedure
outlined in Scheme 3. 2,3-Dichlorophenylacetic acid (16) was treated with thionyl chloride
to give the corresponding acid chloride 17. (R)-4-Benzyl-2-oxazolidinone (18) was
deprotonated with n-butyllithium at −78 °C, and then the generated anion was quenched
with 17 to give 1914. Diastereoselective methylation of 19 was carried out by treating this
substrate with 1M solution of sodium bis(trimethylsilyl)amide at −78 °C, followed by the
addition of iodomethane to give 20 with excellent diastereoselectivity14. Hydrolysis of 20
with lithium peroxide at lower temperature gave acid 21, which was subsequently converted
to amide 22.
Replacement of the amide functional group of 1 with a bioisosteric 1,2,3-triazole was also
investigated. This strategy had previously been successful with one structural class of
CpIMPDH inhibitors10a, but not with another.10d The 1,2,3-triazole derivative of 1 was
prepared according to the method depicted in Scheme 5. Propargyl ether 28 was synthesized
using a Mitsunobu procedure. Then 2-(thiazol-5-yl)benzo[d]oxazol-5-amine (4, R1 = 5-
thiazole, X = H) was converted to the corresponding diazonium chloride followed by
quenching with sodium azide to yield 29. Finally, a CuI mediated reaction of alkyne 28 with
azide 29 gave 30 15.
An analogue in which the benzoxazole ring was replaced with a 1,3-diamide was generated
using the method outlined in Scheme 6. 3-Nitroaniline 31 was coupled with isonicotinic acid
to yield amide 32. Tin mediated reduction of 32 gave 33, which was coupled with (S)-2-
(3,4-di-chlorophenoxy) propionic acid to generate 34.
Regioisomers of 1 were prepared using the procedures outlined in Scheme 8. 2-Amino-5-
nitrophenol (37) and aromatic aldehydes were condensed and oxidized in the presence of
activated carbon (DarcoKB) to give 3811. Reductive hydrogenation of 38 in presence of
10% Pd-C provided 6-amino-2-aryl benzoxazoles 39. Subsequently, amines 39 were
coupled with (S)-2-(2,3-di-chlorophenoxy) propionic acid with the aid of EDCI•HCl to yield
40.
Evaluation of CpIMPDH inhibition
CpIMPDH and hIMPDH2 were expressed and purified as previously described (note that C.
hominis IMPDH is identical to CpIMPDH)16. Enzymatic activity was assayed by
monitoring the production of NADH9. IC50 values reported herein were determined from the
average of three independent experiments, unless otherwise noted. IC50 values were also
measured in the presence of 0.05% fatty acid free bovine serum albumin (BSA) in order to
assess nonspecific protein binding17. Our previous experience indicates that IC50 values in
the presence of BSA are a better predictor of antiparasitic activity18. None of the compounds
significantly inhibited hIMPDH2 (IC50 >5μM).
Initially the aryl ether substituent was evaluated (Table 1). Removal of the 4-chloro group
(41) resulted in a two-fold increase in inhibitory activity, whereas removal of the 2-chloro
group (42) gave a two-fold loss in activity. Removal of both chlorine atoms resulted in
activity comparable to the parent compound 1. The electron donating substitution 4-OMe
(44) demonstrated comparable activity to 41. Translocation of the chlorine atom in 41 from
the 2-position to the 3-position (45) was well tolerated. Combining these changes by
utilizing a 2,3-di-chloro substituted phenyl ether (46) gave a five-fold increase in activity
compared to 41 and 45. However, the 2,6-di-chloro phenyl ether derivative 47 was devoid of
activity. Transforming the 2,3-dichlorophenyl into a 1-naphthyl resulted in a potent inhibitor
Gorla et al. Page 3
J Med Chem. Author manuscript; available in PMC 2014 May 23.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
(48) with an IC50 value of 9 nM, which only increased slightly in the presence of BSA.
These results suggest that the sterics of this group are an important determinant for binding.
However, addition of a chlorine atom to the naphthyl group in the 4-position (49) was
detrimental.
Next, the importance of amide methylene group was examined (Table 2). Removal of the α-
methyl (50) or addition of another α-methyl (51) at this position resulted in complete loss of
activity. Replacing the methyl with a larger isopropyl (52) resulted in approximately a three-
fold loss of activity compared to 48. The enantiomers of 48 were also investigated and found
to demonstrate a stereochemical preference. The (S)-isomer (54, IC50 = 6.1 nM, IC50 = 8
nM in the presence of BSA) was significantly more potent than the (R)-isomer (53, IC50 =
400 nM). Again the (S)-isomers of several other derivatives containing electron withdrawing
groups at the 2,3-positions of the phenyl ether (55, 56 and 57) demonstrated excellent
CpIMPDH inhibitory activities (IC50 < 10 nM). However, the (S)-isomer of the 2,3-di-
methoxy derivative 58 was less active (IC50 = 50 nM).
The importance of the pyridine substituent was subsequently examined (Table 3). Replacing
the pyridine with phenyl (59) resulted in complete loss of activity (IC50 > 5 YM).
Translocation of the nitrogen to the 2-or 3-positions (60 and 61) resulted in a 3- to 4-fold
loss in potency. However, evaluation of derivatives 62 and 63 indicated that a 5-thiazole was
an excellent replacement of the 4-pyridyl, while the 2-thiazole (65) and 2-pyrrole (66)
derivatives resulted in loss of activity compared to 55 and 54, respectively. Finally, the 2-
pyrimidine derivative 67 proved to be inactive.
Following initial assessments of the phenyl ether, the amide α-methylene and the pyridine
moieties in inhibitor 1, a variety of other changes were explored for the amide and central
heterocycle (Table 4). For example, bioisosteric replacement of the amide with a 1,2,3-
triazole (30), N-methylation of the amide nitrogen (9) or inversion of the amide (36) all
resulted in loss of inhibitory activity. However, regioisomers produced by transposing the
amide from the 5-position of the benzoxazole to the 6-position (40a and 40b), surprisingly,
resulted in compounds with excellent CpIMPDH inhibitory activity (IC50 < 10 nM),
although the relative effect of BSA appeared to be slightly greater compared to 55 and 62,
respectively. Addition of a chlorine atom to the 7-position of the benzoxazole of 55 resulted
in 68 and significantly eroded CpIMPDH inhibitory activity. Finally, replacing the
benzoxazole with a benzimidazole (26) or opening of the oxazole ring (34) lead to loss of
inhibitory activity.
The next perturbation examined was to replace the ether C-O bond with a C-C bond (Table
5). In the first iteration, a methylene substituted for the oxygen atom (69), which resulted in
loss of inhibitory activity. However, deletion of the oxygen atom, generating a phenyl
acetamide derivative, resulted in moderately potent inhibition (70, IC50 = 120 nM).
Interestingly, the stereochemical preference of the phenyl acetamide derivatives was the
opposite of the ether derivatives. For example, the (S)-isomer 71 was inactive, while the (R)-
isomer 72 displayed an IC50 value of 22 nM. Another example was investigated to confirm
this observation. The (R)-2,3-di-chlorophenyl derivative 22 was found to be a moderately
potent CpIMPDH inhibitor, although it was less active than the (S)-ether 55.
Given the interesting results obtained with replacing the C-O bond of 1 with a C-C bond, the
ether was exchanged with a secondary amine (Table 6). The 2,3-dichlorophenyl amine
derivative 73 demonstrated slightly improved activity compared to the corresponding 2,3-
dichlorophenyl ether 46. In addition, the (S)-isomer 15a proved to be a very potent
CpIMPDH inhibitor (IC50 = 0.5 nM), although the (S)-naphthyl amine derivative 15b was
less active (IC50 = 14 nM).
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Evaluation of kinetic mechanism for CpIMPDH inhibition
The high throughput screen was designed to target the cofactor site since this site is the most
diverged, and therefore most likely to yield inhibitors selective for the parasite enzyme.9
CpIMPDH, like other IMPDHs characterized to date, has a kinetic mechanism wherein
substrates bind randomly and hydride transfer occurs forming a covalent E-XMP*
intermediate and NADH.7 Products dissociate in an ordered fashion, with NADH release
occurring before the hydrolysis and release of E-XMP*. In principle, IMPDH inhibitors that
bind in the cofactor site can be competitive, uncompetitive or noncompetitive, depending on
their relative affinities for the E, E•IMP and E-XMP* complexes. In practice, most such
inhibitors are noncompetitive, suggesting comparable affinities for E•IMP and E-XMP*.
Uncompetitive inhibition is also commonly observed, indicating a strong preference for E-
XMP*. The inhibition mechanisms of four representative inhibitors (1, 63, 68 and 72) were
evaluated. Surprisingly, the inhibition data with respect to NAD+ for all four compounds
were best fit by competitive mechanism (Figure 3 and Table 7). However, the fit to a
noncompetitve/mixed inhibition was not significantly inferior. This ambiguity is a
consequence of NAD+ substrate inhibition, which prevents the use of saturating NAD+
concentrations.7 This observation suggests that these compounds have a strong preference
for E•IMP. All four compounds are noncompetitive inhibitors with respect to IMP.
Mouse liver microsomal stability
A selected set of the CpIMPDH inhibitors was evaluated for metabolic stability in mouse
liver microsomes (Table 8). Compounds were incubated with microsomes at 37 °C in the
presence and absence of NADPH. The percentage of compound remaining at various time
points was determined and then the data were fit to a first-order decay model to determine
half-life. Three ether derivatives (55, 62 and 40a) demonstrated poor stability in both the
presence and absence of NADPH (t½ ≤ 12 min), whereas 54 was moderately more stable (t½
= 30 min). In the case of two phenyl acetamide derivatives, the unsubstituted inhibitor 72
proved more stable (t½ = 43 min) compared to the 2,3-di-chlorophenyl inhibitor 22 (t½ = 25
min) in the presence of NADPH. Both compounds were quite stable in the absence of
NADPH. For the amine derivatives, the 2,3-di-chlorophenyl inhibitor 15a also displayed
moderate stability in the presence of NADPH (t½ = 44 min), whereas the naphthyl derivative
15b was less stable in the presence or absence of NADPH (t½ = 18 min and 27 min,
respectively).
The structure of CpIMPDH in complex with 54 and IMP
The structure of CpIMPDH in complex with IMP and 54 was solved at 2.10 Å resolution
using molecular replacement with the structure of apo CpIMPDH (PDB ID code 3FFS) as
the search model (Table S1). The structure (Figure 3A) revealed that the inhibitor binds in
the active site and interacts with residues from two adjacent subunits, similarly as previously
observed in the structure of CpIMPDH with C64 (PDB ID code 3KHJ)10b. This binding
mode is significantly different compared to hIMPDH inhibitors and it likely accounts for the
selectivity of the benzoxazole compounds. Inhibitors of mammalian IMPDH such as
mycophenolic acid (MPA) bind in the nicotinamide subsite and interact directly with the
purine ring of the substrate, IMP. In addition, the MPA interaction extends into the adenine
subside. However, the interactions for MPA are limited to the residues within the same
monomer (Figure 3B). In contrast, the naphthalene of 54 stacks against the purine ring of
IMP, in a manner similar to the 2-thiazole of C64, with the remainder of 54 extending across
the subunit interface into the pocket in the adjacent monomer. Unlike C64, the 2-(4-
pyridyl)benzoxazole of 54 fills much of this cavity and the pyridine nitrogen of 54
participates in a water-mediated hydrogen bond with the L170 main chain amide nitrogen
(Figures 3A and 4). This hydrogen bond can account for the requirement of the 4-pyridyl or
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5-thiazolyl substituents. These additional interactions are likely to explain the increased
affinity of 54 relative to C64 (IC50 = 28 nM and 6 nM for C64 and 54, respectively). The
structure also reveals that the (S)-methyl group of 54 forms a hydrophobic interaction with
M308. Inverting this center to the (R)-isomer would likely introduce a steric clash with
E329, which forms a hydrogen bond with the amide NH of 54 and along with S354′ (where
′ denotes a residue from the adjacent subunit) and T221 forms a hydrogen bonding network
with Y358′ (Figures 3A and 4). These observations provide a rationale for the observed
stereochemical preference with regard to the substituent on the amide α-position in the ether
and amine derivatives. In addition, the benzo-portion of the benzoxazole ring of 54 appears
to interact with the side-chain of Y358′.
Evaluation of antiparasitic activity
Although the generation of potent CpIMPDH inhibitors has been accomplished with several
structurally distinct compound classes, achieving antiparasitic activity in C. parvum remains
a challenge. This organism cannot be continuously cultured in vitro, so such assays are poor
mimics of in vivo infection in addition to having a poor dynamic range. However, the
related intracellular parasite T. gondii has proven to be a well behaved organism that can be
engineered to express fluorescent markers, facilitating its use in screening.20 Previously, we
genetically engineered a T. gondii strain that relies on CpIMPDH (Toxo/CpIMPDH) to
synthesize guanine nucleotides.18 In contrast, the wild type T. gondii strain RH (Toxo/WT)
contains a eukaryotic IMPDH that is resistant to CpIMPDH inhibitors, thus providing target
validation as well as a measure of host cell cytotoxicity18.
A set of twenty-two CpIMPDH inhibitors were evaluated for activity in both Toxo/
CpIMPDH and Toxo/WT assays (Table 9). Four compounds (46, 48, 40a and 73)
demonstrated EC50 values ≤ 250 nM in the Toxo/CpIMPDH assay and selectivity > 30-fold
versus Toxo/WT. Thus, the 2,3-dichlorophenyl or 1-naphthyl ethers or amines at either the
5- or -6-positions of the 2-(4-pyridyl)- or 2-(thiazolyl)benzoxazoles translated into
encouraging antiparasitic activity. Furthermore, two of these compounds (40a and 73)
demonstrated EC50 values ≤ 30 nM and selectivity > 150-fold, indicating that the 2,3-
dichlorophenyl ether or amine at either the 5- or 6-positions of the 2-(4-pyridyl)benzoxazole
might be preferable. Based on the in vitro and cellular properties, these compounds are
candidates for evaluation in an animal model of cryptosporidiosis.
Evaluation of mammalian cytotoxicity activity
A subset of compounds (15a, 40a, 41, 44, 46 and 57) were also evaluated for cytotoxicity
against four mammalian cell lines (HeLa, HEK293, COS and CHO). Viability was
determined by monitoring metabolic activity with alamarBlue® assay. None of the
compounds displayed significant toxicity (LD50 > 50 μM) against all four cell lines, except
41 which exhibited an LD50 ~ 12.5 μM in HEK293 cells.
Conclusions
A SAR study of CpIMPDH inhibitor 1 revealed that 2,3-di-substituted phenyl ethers
improved potency, while a 4-pyridyl or 5-thiazolyl group was necessary at the 2-position of
the benzoxazole. In addition, the (S)-isomers were significantly more potent compared to the
corresponding (R)-isomers, but the connectivity of the amide could be transposed from the
5-position of the benzoxazole to the 6-position. The ether oxygen atom could be deleted
generating α-arylamides where the chiral preference switched with the (R)-isomer being
more potent. Furthermore, the ether oxygen atom could be replaced with an NH without
jeopardizing potent CpIMPDH inhibitory activity and again the (S)-isomer was preferred.
The secondary amine derivative 15a (Q67) or its racemic version 73 demonstrated excellent
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CpIMPDH inhibitory activity in the presence or absence of BSA and moderate stability in
the presence of mouse liver microsomes, as well as superb activity and selectivity in a T.
gondii surrogate cell assay of C. parvum infection and no significant cytotoxicity against a
panel of four mammalian cells. Finally, a co-crystal structure of CpIMPDH with IMP and 54
(Q21) allowed for a more complete understanding of the structure-activity relationships
observed with the benzoxazole inhibitors and also demonstrated that this compound series
adopts a similar binding mode as a structurally distinct and previously reported CpIMPDH
inhibitor C64.10b This information should assist in the continuing development of
CpIMPDH inhibitors that will allow for further understanding of this apicomplexan parasite
and its host interactions, advancing the treatment of cryptosporidiosis.
Experimental Section
Chemistry Material and Methods
Unless otherwise noted, all reagents and solvents were purchased from commercial sources
and used without further purification. Compounds 1, 50, 51, 60 and 61 were purchased from
Chembridge Corporation (San Diego, CA 92121, USA). All reactions were performed under
a nitrogen atmosphere in dried glassware unless otherwise noted. All NMR spectra were
obtained using a 400 MHz spectrometer and conducted in CDCl3, unless otherwise
indicated. For 1H NMR, all chemical shifts are reported in δ units ppm and are referenced to
tetramethylsilane (TMS). All chemical shift values are also reported with multiplicity,
coupling constants and proton count. Likewise, for 13C NMR, all chemical shifts are
reported in δ units ppm and are referenced to the central line of the triplet at 77.23 ppm for
those conducted in CDCl3. Coupling constants (J values) are reported in hertz. Column
chromatography was carried out on SILICYCLE SiliaFlash silica gel F60 (40–63 μm, mesh
230–400). High-resolution mass spectra (HRMS) were obtained using a Q-tof UE521 mass
spectrometer (University of Illinois, SCS, and Mass Spectrometry Lab).
HPLC conditions
All final compounds have a chemical purity >98% as determined by analysis using a Agilent
1100 HPLC instrument equipped with a quaternary pump and a Zorbax® SB-C8 column (30
× 4.6 mm, 3.5 mm). UV absorption was monitored at 254 nm. The injection volume was 5
μL. HPLC gradient was 5 % acetonitrile and 95 % water (both solvents contain 0.1%
trifluoroacetic acid) with a total run time of 2.5 min and a flow rate of 3.0 mL/min.
Enantiomeric purity was determined using HPLC analysis on a Agilent 1100 Series
instrument equipped with a quaternary pump using a Chiralpak AS-H Column (250 × 4.6
mm) for all chiral compounds unless noted. The UV absorption was monitored at 254 nm
and the injection volume was 10 μL. A Chiralpak OD-H column was used for 22, 40a, 40b
and 58, and an OJ-H column was used for 15b, 73 and 74. For these latter two columns the
UV absorption was monitored at 220 nm and an injection volume 20 μL was used. HPLC
gradient for all compounds was 70 % n-hexane and 30 % i-propanol and a flow rate of 1.0
mL/min.
General procedure for the preparation of 5-nitro-2-arylbenzo[d]oxazoles (3).
Exemplified for 5-nitro-2-(pyridine-4-yl)benzo[d]oxazole (3, R1 = 4-Py, X = H)—
To a solution of 2-amino-4-nitrophenol (500 mg, 3.24 mmol) in anhydrous xylene (10 mL)
in a 100 mL three-neck flask under an oxygen atmosphere was added 4-pyridine
carboxaldehyde (347 mg, 3.23 mmol) and Darco KB (600 mg). The solution was stirred at
120 °C for 4 h. The reaction mixture was allowed to cool to room temperature and then
filtered with the aid of Celite. The filtrate was concentrated and the residue was purified by
silica gel column chromatography using a mixture of ethyl acetate/n-hexane (50:50) to give
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5-nitro-2-(pyridine-4-yl)benzo[d]oxazole (600 mg, 77%) as a yellow solid. 1H NMR
(CDCl3, 400 MHz) δ 7.76 (d, J = 9.2 Hz, 1H), 8.11 (d, J = 6 Hz, 2H), 8.40 (d, J1 = 12 Hz, J2
= 2.4 Hz, 1H), 8.73 (d, J = 2 Hz, 1H), 8.89 (d, J = 6 Hz, 2H).
General procedure for the preparation of 5-amino-2-aryl-benzo[d]oxazoles (4).
Exemplified for 5-amino-2-(pyridine-4-yl)benzo[d]oxazole (4, R1 = 4-Py, X = H)
—To a solution of 5-nitro-2-(pyridine-4-yl)benzo[d]oxazole (600 mg, 2.48 mmol) in ethyl
acetate/MeOH (1:1, 10 mL) was added a catalytic amount of 10% Pd-C. The reaction
mixture was placed under a hydrogen atmosphere and stirred for 6 h at room temperature.
The mixture was then filtered, concentrated and the residue purified by flash column
chromatography on silica gel using 100% ethyl acetate as eluent to afford 5-amino-2-
(pyridine-4-yl)benzo[d]oxazole (450 mg, 86%) as a yellow solid. 1H NMR (CDCl3, 400
MHz) δ 6.78 (dd, J1 = 12 Hz, J2 = 2.4 Hz, 1H), 7.07 (d, J = 2 Hz, 1H), 7.40 (d, J = 4.8 Hz,
1H), 8.05 (dd, J1 = 8 Hz, J2 = 1.6 Hz, 2H), 8.79 (dd, J1 = 4 Hz, J2 = 1.6 Hz, 2H), 3.78 (s,
2H).
General procedure for the preparation of (±)-7. Exemplified for 2-(2,3-
dichlorophenoxy)propionic acid (7, R2 = 2,3-di-ClPh, R3 = Me, Y = O)—To a
solution of 2,3-dichlorophenol (200 mg, 1.22mmol) in anhydrous DMF (15 mL) was added
K2CO3 (505 mg, 3.66 mmol) and ethyl 2-bromopropionate (287.1 mg, 1.58 mmol). The
reaction mixture was stirred at room temperature for 5 h under a nitrogen atmosphere,
diluted with water (50 mL) and extracted with ethyl acetate (3 X 50 mL). Note, when Y =
NH this reaction was conducted at 70 °C for 3 h. The organic extracts were combined,
washed with brine, dried over anhydrous MgSO4, filtered and concentrated in vacuo. The
residue was purified by silica gel column chromatography using a mixture of ethyl acetate
and n-hexane (10:90) to give ethyl 2-(2,3-dichlorophenoxy)propionate (290 mg, 1.2 mmol,
90%) as a colorless liquid. The ester (290 mg, 1.60 mmol) was dissolved in THF: H2O (2:1),
and then NaOH (132 mg, 3.3 mmol) was added. The reaction mixture was heated at 80 °C
for 3 h. After the reaction mixture was allowed to cool to room temperature, 1N HCl was
added until a pH of 7 was reached and then the mixture was extracted with DCM. The
organic layers were dried over anhydrous MgSO4, filtered, and concentrated. The residue
was purified by silica gel column chromatography using a mixture of ethyl acetate/n-hexane
(60:40) to afford 2-(2,3-dichlorophenoxy)propionic acid (270 mg, 95%) as a white solid.
General procedure for the preparation of (R)- and (S)-7. Exemplified for (S)-2-
(2,3-dichlorophenoxy)propionic acid (7, R2 = 2,3-di-ClPh, R3 = (S)-Me, Y = O)—
2,3-Dichlorophenol (150 mg, 0.92 mmol) was dissolved in anhydrous DCM (6 mL) under a
nitrogen atmosphere and then methyl (R)-(+)-2-(4-hydroxyphenoxy)propionate (143.7 mg,
1.38 mmol) was added. After the reaction mixture was cooled to 0 °C, PPh3 (289.4 mg, 1.10
mmol) was added portion-wise and the reaction mixture was stirred for 10 minutes. Then
DEAD (240 mg, 1.37 mmol) was slowly added. The reaction mixture was stirred for 12 h at
room temperature and then 10 mL of water was added and the mixture extracted with DCM.
The organic layers were washed with brine, dried over anhydrous MgSO4, filtered and
concentrated. The residue was purified by column chromatography on silica gel using ethyl
acetate/n-hexane (10:90) to yield methyl (S)-2-(2,3-dichlorophenoxy)propionate (180 mg,
0.76 mmol, 83%) as a colorless liquid. The ester (180 mg, 0.72 mmol) was added to a
mixture of 6 mL THF in 3N HCl (2:8), and then heated at 70 °C for 6 h. The reaction
mixture was allowed to cool to room temperature then extracted with DCM. Organic layers
were washed with brine, dried over anhydrous MgSO4, filtered, and concentrated. The
residue was purified by silica gel column chromatography using ethyl acetate/n-hexane
(60:40) to afford (S)-2-(2,3-dichlorophenoxy)propionic acid (110 mg, 62%) as a white
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solid. 1H NMR (CDCl3, 400 MHz) δ 1.51(d, J = 7.2 Hz, 3H), 4.27 (q, J = 7.2 Hz, 1H), 7.16
– 7.24 (m, 2H), 7.37 (dd, J1 = 3.6 Hz, J2 = 1.6 Hz, 1H).
General procedure for the preparation of benzoxazoles (8). Exemplified for
(S)-2-(2,3-dichlorophenoxy)-N-(2-(pyridin-4-yl)benzo[d]oxazol-5-
yl)propionamide (55)—To a solution of 5-amino-2-(pyridine-4-yl)benzo[d]oxazole
(266.7 mg, 1.27 mmol) and (S)-2-(2,3-dichlorophenoxy)propionic acid (300 mg, 1.27 mmol)
were dissolved in anhydrous DMF (5 mL) under a nitrogen atmosphere. The reaction
mixture was cooled to 0 °C and then EDCI•HCl (489.6 mg, 2.55 mmol) was added. The
reaction mixture was stirred for 12 h at room temperature. Volatiles were removed under
reduced pressure and the mixture was dissolved in 20 mL DCM. The organic layer was
washed sequentially with a saturated aqueous solution of sodium bicarbonate and brine. The
organic layers were dried over anhydrous MgSO4, filtered, and concentrated. The residue
was purified by silica gel column chromatography using ethyl acetate/n-hexane (50:50) to
give 55 (390 mg, 72%) as a white solid. 1H NMR (CDCl3, 400 MHz) δ 1.76 (d, J = 6.8 Hz,
3H), 4.90 (q, J = 6.8 Hz, 1H), 6.93 (dd, J1 = 7.2 Hz, J2 = 2.4 Hz, 1H), 7.17 – 7.23 (m, 2H),
7.56 – 7.61 (m, 2H), 8.06 (dd, J1 = 4 Hz, J2 = 1.6 Hz, 2H), 8.17 (s, 1H), 8.81 – 8.83 (m,
3H); 13C NMR (CDCl3, 100 MHz) δ 18.6, 76.9, 111.2, 112.1, 113.2, 119.2, 121.2, 122.9,
124.3, 128.1, 134.3, 134.5, 134.7, 142.4, 148.0, 150.9, 153.7, 161.8, 169.2; ESIHRMS for
C21H16N3O3Cl2 (M+H)+ calcd. 428.0569, found 428.0568, Chiral purity (% ee > 98,
tR=12.84 min).
The following compounds were prepared in a similar manner:
2-(2-chlorophenoxy)-N-(2-(pyridine-4-yl)benzo[d]oxazol-5-yl)propionamide (41): 71%;
white solid; 1H NMR (CDCl3, 400 MHz) δ 1.77 (d, J = 6.4 Hz, 3H), 4.90 (q, J = 6.8 Hz,
1H), 7.02 (t, J = 7.6 Hz, 2H), 7.25 – 7.29 (m, 1H), 7.45 (d, J = 8 Hz, 1H), 7.57 (d, J = 8.4
Hz, 1H), 7.64 (dd, J1 = 8 Hz, J2 = 2 Hz, 1H), 8.06 (d, J = 5.2 Hz, 2H), 8.17 (s, 1H), 8.82 (d, J
= 4.4 Hz, 2H), 8.95 (s, 1H); 13C NMR (CDCl3, 100 MHz) δ 18.7, 76.8, 111.1, 111.9, 115.6,
119.2, 121.1, 123.5, 123.8, 128.4, 130.8, 134.3, 134.9, 142.3, 147.9, 150.9, 152.4, 161.7,
169.5; ESI-HRMS for C21H17N3O3Cl (M+H)+ calcd. 394.0958 found 394.0961.
2-(4-chlorophenoxy)-N-(2-(pyridine-4-yl)benzo[d]oxazol-5-yl)propionamide (42): 72%;
white solid; 1H NMR (CDCl3, 400 MHz) δ 1.69 (d, J = 6.8 Hz, 3H), 4.79 (q, J = 6.8 Hz,
1H), 6.94 (d, J = 8.8 Hz, 2H), 7.30 (d, J = 8.4 Hz, 2H), 7.51 – 7.58 (m, 2H), 8.08 (dd, J1 = 10
Hz, J2 = 2 Hz, 3H), 8.29 (s, 1H), 8.82 (d = 4.8 Hz, 2H); 13C NMR (CDCl3, 100 MHz) δ
18.8, 76.0, 111.2, 112.5, 117.3, 119.5, 121.2, 127.8, 130.1, 134.3, 134.5, 142.4, 148.1,
150.9, 155.3, 161.8, 170.1; ESI-HRMS for C21H17N3O3Cl (M+H)+ calcd. 394.0958 found
394.0961.
2-phenoxy-N-(2-(pyridine-4-yl)benzo[d]oxazol-5-yl)propionamide (43): 63%; white
solid; 1H NMR (CDCl3, 400 MHz) δ 1.69 (d, J = 6.4 Hz, 3H), 4.84 (q, J = 6.4 Hz, 1H), 7.07
– 6.99 (m, 3H), 7.34 (t, J = 8 Hz, 2H), 7.54 (t, J = 8.4 Hz, 2H), 8.08 (d, J = 13.6 Hz, 3H),
8.42 (s, 1H), 8.82 (s, 2H); 13C NMR (CDCl3, 100 MHz) δ 18.9, 75.6, 111.1, 112.4, 115.9,
119.6, 120.5, 121.2, 121.2, 121.3, 122.7, 128.1, 130.1, 134.3, 134.6, 142.4, 148.0, 150.9,
156.8, 161.7, 170.6; ESI-HRMS for C21H18N3O3 (M+H)+ calcd. 360.1348, found 360.1350.
2-(4-methoxyphenoxy)-N-(2-(pyridine-4-yl)benzo[d]oxazol-5-yl)propionamide (44):
73%; white solid; 1H NMR (CDCl3, 400 MHz) δ 1.66 (d, J = 6.8 Hz, 3H), 3.78 (s, 3H), 4.72
(q, J = 6.8 Hz, 1H), 6.86 (d, J = 9.2 Hz, 2H), 6.94 (d, J = 9.2 Hz, 2H), 7.56 (s, 2H), 8.07 (d, J
= 6 Hz, 2H), 8.11 (s, 1H), 8.44 (s, 1H), 8.81 (d, J = 6 Hz, 2H); 13C NMR (CDCl3, 100 MHz)
δ 18.8, 55.8, 76.6, 94.6, 111.1, 112.3, 115.1, 117.4, 119.5, 121.2, 134.3, 134.7, 142.4, 148.0,
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150.9, 155.2, 161.7, 170.8; ESI-HRMS for C22H20N3O4 (M+H)+ calcd. 390.1454 found
390.1457.
2-(3-chlorophenoxy)-N-(2-(pyridine-4-yl)benzo[d]oxazol-5-yl)propionamide (45): 73%;
white solid; 1H NMR (CDCl3, 400 MHz) δ 1.68 (d, J = 6.8 Hz, 3H), 4.82 (q, J = 6.8 Hz,
1H), 6.86 – 6.89 (m, 1H), 7.02 (d, J = 7.6 Hz, 2H), 7.23 – 7.27 (m, 1H), 7.51 – 7.57 (m, 2H),
8.05 (d, J = 5.2 Hz, 2H), 8.09 (s, 1H), 8.37 (s, 1H), 8.81 (s, 2H); 13C NMR (CDCl3, 100
MHz) δ 18.7, 75.8, 111.1, 112.5, 113.8, 116.8, 119.6, 121.2, 123.0, 130.9, 134.2, 134.5,
135.5, 142.4, 148.1, 150.9, 157.4, 161.7, 170.0; ESIHRMS for C21H17N3O3Cl (M+H)+
calcd. 394.0958, found 394.0959.
2-(2,3-dichlorophenoxy)-N-(2-(pyridine-4-yl)benzo[d]oxazol-5-yl)propionamide (46):
71%; white solid; 1H NMR (CDCl3, 400 MHz) δ 1.77 (d, J = 6.8 Hz, 3H), 4.91 (q, J = 6.8
Hz, 1H), 6.93 (dd, J1 = 6.6 Hz, J2 = 2.8 Hz, 1H), 7.20 – 7.23 (m, 2H), 7.60 (d, J = 1.2 Hz,
2H), 8.08 (d, J = 4.4 Hz, 2H), 8.18 (s, 1H), 8.83 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ
18.3, 76.6, 111.0, 111.8, 113.0, 119.0, 120.9, 122.7, 124.1, 127.8, 134.1, 134.3, 134.5,
142.2, 147.8, 150.7, 153.5, 161.5, 168.9; ESI-HRMS for C21H16N3O3Cl2 (M+H)+ calcd.
428.0569, found 428.0569.
2-(2,6-dichlorophenoxy)-N-(2-(pyridine-4-yl)benzo[d]oxazol-5-yl)propionamide (47):
67%; white solid; 1H NMR (CDCl3, 400 MHz) δ 1.61 (d, J = 6.8 Hz, 3H), 5.11 (q, J = 6.8
Hz, 1H), 7.09 (t, J = 7.6 Hz, 1H), 7.37 (d, J = 8.4 Hz, 2H), 7.60 (d, J = 8.8 Hz, 1H), 7.18 (dd,
J1 = 8.8 Hz, J2 = 1.6 Hz, 1H), 8.08 (d, J = 5.2 Hz, 2H), 8.20 (s, 1H), 8.82 (d, J = 5.2 Hz, 2H),
8.99 (s, 1H); 13C NMR (CDCl3, 100 MHz) δ 18.2, 79.5, 111.1, 112.1, 119.4, 121.2, 126.1,
129.5, 129.6, 134.3, 135.0, 142.4, 148.0, 148.7, 150.9, 169.5, 195.9; ESI-HRMS for
C21H16N3O3Cl2 (M+H)+ calcd. 428.0569, found 428.0567.
2-(naphthalene-1-yloxy)-N-(2-(pyridine-4-yl)benzo[d]oxazol-5-yl)propionamide (48):
73%; white solid; 1H NMR (CDCl3, 400 MHz) δ 1.84 (d, J = 6.4 Hz, 3H), 5.04 (q, J = 6.8
Hz, 1H), 6.92 (d, J = 7.6 Hz, 1H), 7.39 (t, J = 8 Hz, 1H), 7.61 – 7.48 (m, 5H), 7.89 – 7.86
(m,1H), 8.05 – 8.08 (m, 3H), 8.33 – 8.36 (m, 1H), 8.41 (s, 1H), 8.80 (s, 2H); 13C NMR
(CDCl3, 100 MHz) δ 19.1, 76.2, 107.3, 111.1, 112.4, 119.6, 121.21, 121.25, 121.5, 122.4,
125.8, 126.0, 126.1, 127.0, 128.1, 134.2, 134.6, 134.9, 142.4, 148.0, 150.9, 152.6, 170.6;
ESI-HRMS for C25H20N3O3 (M+H)+ calcd. 410.1505, found 410.1508.
2-(4-chloronaphthalen-1-yloxy)-N-(2-(pyridin-4-yl)benzo[d]oxazol-5-yl)propionamide
(49): 68%; white solid. 1H NMR (CDCl3, 400 MHz) δ 1.83 (d, J = 6.8 Hz, 3H), 5.0 (q, J =
6.8 Hz, 1H), 6.84 (d, J = 8.4 Hz, 1H), 7.46 – 7.50 (m, 2H), 7.54 (d, J = 8.8 Hz, 1H), 7.63 –
7.71 (m, 2H), 8.04 – 8.07 (m, 3H), 8.27 (d, J = 8 Hz, 1H), 8.36 (d, J = 8 Hz, 2H), 8.81 (d, J =
4 Hz, 2H); 13C NMR (CDCl3, 100 MHz) δ 19.0, 76.5, 107.3, 111.1, 112.5, 119.6, 121.1,
122.0, 124.9, 125.5, 125.9, 126.9, 128.1, 131.8, 134.2, 134.4, 134.4, 134.7, 142.4, 148.1,
150.9, 151.7, 161.8, 170.3; ESI-HRMS for C25H19N3O3Cl (M+H)+ calcd. 444.1115, found
444.1119.
3-methyl-2-(naphthalene-1-yloxy)-N-(2-(pyridine-4-yl)benzo[d]oxazol-5-yl)butanamide
(52): 67%; white solid; 1H NMR (CDCl3, 400 MHz) δ 1.18 (d, J = 6.8 Hz, 3H), 1.25 (d, J =
6.8 Hz, 3H), 2.51 – 2.59 (m, 1H), 4.69 (d, J = 4 Hz, 1H), 6.84 (d, J = 7.6 Hz, 1H), 7.31 (t, J
= 8 Hz, 1H), 7.37 – 7.47 (m, 3H), 7.51 – 7.54 (m, 2H), 7.80 (t, J = 6.4 Hz, 1H), 7.95 – 7.97
(m, 3H), 8.34 (d, J = 5.6 Hz, 2H), 8.72 (d, J = 5.2 Hz, 2H); 13C NMR (CDCl3, 100 MHz) δ
17.5, 19.6, 32.5, 84.5, 106.7, 111.0, 112.7, 119.9, 121.1, 121.5, 122.1, 125.7, 126.0, 127.0,
128.1, 134.2, 134.4, 134.8, 142.2, 148.0, 150.7, 153.5, 161.6, 169.8; ESI-HRMS for
C27H24N3O3 (M+H)+ calcd. 438.1818, found 438.1822.
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(R)-2-(naphthalene-1-yloxy))-N-(2-(pyridine-4-yl)benzo[d]oxazol-5-yl)propionamide
(53): 76%; white solid; 1H NMR (CDCl3, 400 MHz) δ 1.83 (d, J = 6.8 Hz, 3H), 5.03 (q, J =
6.8 Hz, 1H), 6.91 (d, J = 7.6 Hz, 1H), 7.38 (t, J = 8 Hz, 1H), 7.50 – 7.58 (m, 5H), 7.85 – 7.87
(m, 1H), 8.03 – 8.07 (m, 3H), 8.34 (t, J = 2.8 Hz, 1H), 8.47 (s, 1H), 8.80 (bs, 2H); 13C NMR
(CDCl3, 100 MHz) δ 19.1, 67.3, 76.2, 107.3, 111.1, 112.4, 119.6, 121.2, 121.5, 122.4,
125.8, 126.0, 126.1, 127.0, 128.1, 134.3, 134.6, 134.9, 142.3, 148.0, 150.9, 152.6, 161.7,
170.6; ESI-HRMS for C25H20N3O3 (M+H)+ calcd. 410.1505, found 410.1508, Chiral purity
(% ee 98.1, tR=22.87).
(S)-2-(naphthalene-1-yloxy))-N-(2-(pyridine-4-yl)benzo[d]oxazol-5-yl)propionamide
(54): 71%; white solid; 1H NMR (CDCl3, 400 MHz) δ 1.78 (d, J = 6.8 Hz, 3H), 4.96 (q, J =
6.8 Hz, 1H), 6.85 (d, J = 7.6 Hz, 1H), 7.30 (t, J = 8 Hz, 1H), 7.50 – 7.42 (m, 5H), 7.77 – 7.79
(m, 1H), 7.92 (dd, J1 = 4.4 Hz, J2 = 1.6 Hz, 2H), 8.02 (s, 1H), 8.26 – 8.23 (m, 1H), 8.60 (s,
1H), 8.70 (d, J = 4.4 Hz, 2H); 13C NMR (CDCl3, 100 MHz) δ 19.1, 76.2, 107.2, 111.0,
112.5, 119.7, 121.1, 121.5, 122.3, 125.0, 125.8, 126.0, 126.9, 128.0, 134.1, 134.7, 134.8,
142.2, 147.9, 150.8, 152.7, 161.6, 170.7; ESI-HRMS for C25H20N3O3 (M+H)+ calcd.
410.1505, found 410.1507, Chiral purity (% ee 98.9, tR=12.08).
(S)-2-(2-chloro-3-(trifluoromethyl)phenoxy)-N-(2-(pyridine-4-yl)benzo[d]oxazol-5-
yl)propionamide (56): 70%; cream colored solid; 1H NMR (CDCl3, 400 MHz) δ 1.78 (d, J
= 6.8 Hz, 3H), 4.94 (q, J = 6.4 Hz, 1H), 7.21 (d, J = 7.6 Hz, 1H), 7.37 – 7.44 (m, 2H), 7.59
(s, 2H), 8.07 (d, J = 5.2 Hz 2H), 8.19 (s, 1H), 8.82 (d, J = 5.6 Hz, 3H); 13C NMR (CDCl3,
100 MHz) δ 18.5, 76.9, 111.2, 112.1, 118.4, 119.2, 121.1, 122.3, 124.0, 130.4, 134.2, 134.6,
142.4, 148.0, 150.9, 153.5, 161.8, 168.9; ESI-HRMS for C22H16N3O3ClF3 (M+H)+ calcd.
462.0832, found 462.0834, Chiral purity (% ee 99.4, tR=11.83).
(S)-2-(2-chloro-3-nitrophenoxy)-N-(2-(pyridine-4-yl)benzo[d]oxazol-5-yl)propionamide
(57): 77%; cream colored solid; 1H NMR (CDCl3, 400 MHz) δ 1.80 (d, J = 6.8 Hz, 3H),
4.97 (q, J = 6.8 Hz, 1H), 7.24 (d, J = 8.4 Hz, 1H), 7.44 (t, J = 8.4 Hz, 1H), 7.53 – 7.62 (m,
3H), 8.07 – 8.09 (m, 2H), 8.20 (s, 1H), 8.68 (s, 1H), 8.82 – 8.84 9m, 2H); 13C NMR (CDCl3,
100 MHz) δ 18.5, 76.9, 111.3, 112.2, 117.2, 118.0, 118.7, 119.3, 121.2, 128.4, 134.2, 134.4,
142.4, 148.1, 149.9, 150.9, 153.7, 161.9, 168.6; ESI-HRMS for C21H16N4O5Cl (M+H)+
calcd. 439.0809, found 439.0805, Chiral purity (% ee >99, tR=35.93).
(S)-2-(2,3-dimethoxyphenoxy)-N-(2-(pyridine-4-yl)benzo[d]oxazol-5-yl)propionamide
(58): 79%; white solid; 1H NMR (CDCl3, 400 MHz) δ 1.78 (d, J = 6.8 Hz, 3H), 3.89 (s,
3H), 4.01 (s, 3H), 4.78 (q, J = 6.8 Hz, 1H), 6.67 – 6.71 (m, 2H), 7.04 (t, J = 5.6 Hz, 1H),
7.55 (d, J = 8.8 Hz, 1H), 7.68 (dd, J1 = 9.2 Hz, J2 = 2.4 Hz, 1H), 8.07 (dd, J1 = 4.4 Hz, J2 =
1.6 Hz, 2H), 8.20 (d, J = 2 Hz, 1H), 8.82 (dd, J1 = 4.4 Hz, J2 = 1.2 Hz, 2H), 9.58 (s, 1H); 13C
NMR (CDCl3, 100 MHz) δ 20.5, 57.0, 62.5, 80.3, 108.3, 111.4, 111.8, 112.7, 120.1, 122.0,
125.7, 135.3, 136.4, 140.4, 143.1, 148.6, 151.7, 152.8, 154.9, 162.4, 171.4; ESI-HRMS for
C23H22N3O5 (M+H)+ calcd. 420.1559, found 420.1557, Chiral purity (% ee >99, tR=17.41).
2-(2,4-dichlorophenoxy)-N-(2-(phenylbenzo[d]oxazol-5-yl)propionamide (59): 73%;
white solid; 1H NMR (CDCl3, 400 MHz) δ 1.74 (d, J = 6.8 Hz, 3H), 4.84 (q, J = 6.8 Hz,
1H), 6.94 (d, J = 8.8 Hz, 1H), 7.23 (dd, J1 = 8.8 Hz, J2 = 2.4 Hz, 1H), 7.44 (d, J = 2.4 Hz,
1H), 7.54 – 7.51 (m,4H), 7.56 (d, J = 2 Hz, 1H), 7.59 (d, J = 2 Hz, 1H), 8.05 (d, J = 1.6 Hz,
1H), 8.24 (dd, J = 8 Hz, 2H), 8.75 (s, 1H); 13C NMR (CDCl3, 100 MHz) δ 18.6, 76.9, 110.8,
111.6, 116.4, 118.0, 124.7, 127.1, 127.8, 128.0, 128.4, 129.1, 130.6, 131.9, 134.2, 142.8,
148.0, 151.3, 164.2, 169.1; ESI-HRMS for C22H17N2O3Cl2 (M+H)+ calcd. 427.0616 found
427.0619.
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(S)-2-(2,3-dichlorophenoxy)-N-(2-(thiazol-5-yl)benzo[d]oxazol-5-yl)propionamide (62):
76%; white solid; 1H NMR (CDCl3, 400 MHz) δ 1.76 (d, J = 6.8 Hz, 3H), 4.89 (q, J = 6.8
Hz, 1H), 6.92 (dd, J1 = 7.2 Hz, J2 = 2.4 Hz, 1H), 7.17 – 7.22 (m, 2H), 7.55 (q, J = 8.8 Hz,
2H), 8.09 (s, 1H), 8.64 (s, 1H), 8.81 (s, 1H); 13C NMR (CDCl3, 100 MHz) δ 18.6, 76.9,
110.9, 111.6, 113.2, 118.6, 120.5, 122.9, 124.3, 125.7, 128.1, 134.7, 142.4, 145.7, 147.6,
153.7, 156.4, 158.0, 169.1; ESI-HRMS for C19H14N3O3SCl2 (M+H)+ calcd. 434.0133,
found 434.0136, Chiral purity (% ee 99.1, tR=15.5).
(S)-2-(naphthalene-1-yloxy)-N-(2-(thiazol-5-yl)benzo[d]oxazol-5-yl)propionamide (63):
78%; white solid; 1H NMR (CDCl3, 400 MHz) δ 1.81 (d, J = 6.8 Hz, 3H), 5.01 (q, J = 6.4
Hz, 1H), 6.89 (d, J = 7.6 Hz, 1H), 7.35 (t, J = 7.6 Hz, 1H), 7.45 – 7.54 (m, 5H), 7.82 (t, J =
4.8 Hz, 1H), 7.96 (s, 1H), 8.29 (d, J = 5.2 Hz, 1H), 8.55 (d, J = 21.6 Hz, 2H), 8.91 (s,
1H); 13C NMR (CDCl3, 100 MHz) δ 19.1, 76.2, 107.3, 110.7, 112.0, 119.0, 121.5, 122.3,
125.6, 125.8, 126.0, 126.1, 127.0, 128.0, 134.6, 134.8, 142.2, 145.6, 147.6, 152.6, 156.4,
157.8, 170.6; ESI-HRMS for C23H18N3O3S (M+H)+ calcd. 416.1069, found 416.1075,
Chiral purity (% ee 98.7, tR=12.53).
2-(4-chloronaphthalen-1-yloxy)-N-(2-(thiazol-5-yl)benzo[d]oxazol-5-yl)propionamide
(64): 64%; white solid; 1H NMR (CDCl3, 400 MHz) δ 1.82 (d, J = 6.8 Hz, 3H), 4.99 (q, J =
6.8 Hz, 1H), 6.83 (d, J = 8.4 Hz, 1H), 7.44 – 7.50 (m, 3H), 7.62 – 7.71 (m, 2H), 7.98 (d, J =
2 Hz, 1H), 8.25 – 8.37 (m, 3H), 8.62 (s, 1H), 8.96 (s, 1H); 13C NMR (CDCl3, 100 MHz) δ
19.1, 76.6, 107.4, 110.9, 112.1, 119.0, 122.0, 125.0, 125.6, 126.0, 126.9, 127.0, 128.2,
131.8, 134.5, 142.4, 145.8, 147.8, 151.7, 156.5, 161.8, 166.4, 170.3; ESI-HRMS for
C23H17N3O3SCl (M+H)+ calcd. 450.0679, found 450.0680.
(S)-2-(2,3-dichlorophenoxy)-N-(2-(thiazol-2-yl)benzo[d]oxazol-5-yl)propionamide (65):
69%; white solid; 1H NMR (CDCl3, 400 MHz) δ 1.72 (d, J = 6.8 Hz, 3H), 4.85 (q, J = 6.8
Hz, 1H), 6.89 (dd, J1 = 8 Hz, J2 = 2 Hz, 1H), 7.12 – 7.18 (m, 2H), 7.55 (bs, 2H), 7.59 (d, J =
2.8 Hz, 1H), 8.03 (d, J = 3.2 Hz, 1H), 8.14 (d, J = 1.2 Hz, 1H); 13C NMR (CDCl3, 100
MHz) δ 18.6, 77.0, 111.5, 112.0, 113.2, 119.5, 122.9, 123.5, 124.3, 128.0, 134.5, 134.9,
142.0, 145.3, 147.8, 153.7, 154.7, 158.0, 169.2; ESI-HRMS for C19H14N3O3SCl2 (M+H)+
calcd. 434.0133, found 434.0132, Chiral purity (% ee >99, tR=12.88).
N-(2-(1H-pyrrol-2-yl)benzo[d]oxazol-5-yl)2-(naphthalene-1-yloxy)propionamide (66):
70%; white solid; 1H NMR (CDCl3, 400 MHz) δ 1.82 (d, J = 6.8 Hz, 3H), 5.02 (q, J = 6.4
Hz, 1H), 6.36 (dd, J1 = 2.4 Hz, J2 = 6 Hz, 1H), 6.91 (d, J = 8 Hz, 1H), 7.06 (d, J = 1.6 Hz,
2H), 7.32 – 7.43 (m,3H), 7.52 – 7.60 (m, 3H), 7.85 – 7.89 (m, 2H), 8.34 (d, J = 12 Hz, 2H),
9.87 (d, J = 1.6 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ 19.1, 76.2, 107.3, 110.4, 111.0,
111.1, 113.7, 117.5, 119.5, 120.5, 121.5, 122.3, 123.6, 126.0, 126.0, 126.1, 127.0, 128.1,
134.1, 134.9, 142.0, 147.2, 152.6, 159.0, 170.5; ESI-HRMS for C24H20N3O3 (M+H)+ calcd.
398.1505, found 398.1509.
2-(naphthalene-1-yloxy)-N-(2-(pyrimidin-2-yl)benzo[d]oxazol-5-yl)propionamide (67):
63%; white solid; 1H NMR (CDCl3, 400 MHz) δ 1.83 (d, J = 6.8 Hz, 3H), 5.04 (q, J = 6.8
Hz, 1H), 6.93 (d, J = 7.6 Hz, 1H), 7.39 (t, J = 8.4 Hz, 1H), 7.61 – 7.53 (m, 4H), 7.88 – 7.86
(m, 1H), 8.09 (s, 1H), 8.34 (d, J = 7.2 Hz, 1H), 8.44 (s, 1H), 8.99 (d, J = 4.8 Hz, 2H); 13C
NMR (CDCl3, 100 MHz) δ 19.1, 76.4, 107.5, 111.7, 111.7, 113.1, 120.5, 121.5, 122.2,
122.4, 125.9, 126.0, 126.1, 127.0, 128.1, 134.8, 134.9, 142.2, 148.4, 152.7, 155.2, 158.2,
170.7; ESI-HRMS for C24H19N4O3 (M+H)+ calcd. 411.1457, found 411.1460.
(S)-N-(7-chloro-2-(pyridin-4-yl)benzo[d]oxazol-5-yl)-2-(2,3-
dichlorophenoxy)propionamide (68): 68%; white solid; 1H NMR (CDCl3, 400 MHz) δ
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1.73 (d, J = 6.8 Hz, 3H), 4.87 (q, J = 6.8 Hz, 1H), 6.90 (dd, J1 = 6.4 Hz, J2 = 3.2 Hz, 1H),
7.18 – 7.23 (m, 2H), 7.75 (d, J = 2 Hz, 1H), 7.97 (d, J = 1.6 Hz, 1H), 8.08 (d, J = 5.2 Hz,
2H), 8.82 (d, J = 8 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 18.5, 77.0, 110.4, 113.3, 116.5,
119.2, 121.3, 124.5, 128.1, 133.7, 134.6, 135.3, 143.2, 144.8, 150.9, 153.6, 162.1, 162.6,
169.3; ESI-HRMS for C21H15N3O3Cl3 (M+H)+ calcd. 462.0179 found 462.0182, Chiral
purity (% ee >99, tR= 4.52).
2-methyl-3-phenyl-N-(2-(pyridine-4-yl)benzo[d]oxazol-5-yl)propionamide (69): 75%;
white solid; 1H NMR (CDCl3, 400 MHz) δ 1.29 (d, J = 6 Hz, 3H), 2.63 (q, J = 6.4 Hz, 1H),
2.77 (dd, J1 = 16 Hz, J2 = 5.6 Hz, 1H), 3.02 (dd, J1 = 16 Hz, J2 = 9.2 Hz, 1H), 7.17 – 7.25
(m, 5H), 7.34 – 7.44 (m, 3H), 7.75 (s, 1H), 7.99 (d, J = 4 Hz, 2H), 8.75 (s, 2H); 13C NMR
(CDCl3, 100 MHz) δ 18.0, 40.9, 44.9, 110.9, 112.5, 120.0, 121.2, 126.7, 128.8, 129.1,
134.4, 135.3, 139.8, 142.1, 147.8, 150.8, 174.3; ESI-HRMS for C22H20N3O2 (M+H)+ calcd.
358.1556 found 358.1556.
2-phenyl-N-(2-(pyridine-4-yl) benzo[d]oxazol-5-yl)propionamide (70): 77%; 1H NMR
(CDCl3, 400 MHz) δ 1.61 (d, J = 7.2 Hz, 3H), 3.74 (q, J = 7.2 Hz, 1H), 7.17 (s, 1H), 7.23 (s,
1H), 7.29 – 7.32 (m, 1H), 7.37 – 7.41 (m, 4H), 7.47 (d, J = 8.8 Hz, 1H), 7.91 (d, J = 1.6 Hz,
1H), 8.01 (dd, J1 = 1.6 Hz, J2 = 1.2 Hz, 2H), 8.77 (d, J = 5.6 Hz, 2H); 13C NMR (CDCl3,
100 MHz) δ 18.8, 48.3, 110.9, 112.1, 119.4, 121.1, 127.92, 127.94, 129.4, 134.3, 135.4,
140.9, 142.3, 147.8, 150.9, 161.6, 172.5; ESI-HRMS for C21H18N3O2 (M+H)+ calcd.
344.1399, found 344.1400.
(S)-2-phenyl-N-(2-(pyridine-4-yl)benzo[d]oxazol-5-yl)propionamide (71): 77%; 1H
NMR (CDCl3, 400 MHz) δ 1.52 (d, J = 7.2 Hz, 3H), 3.67 (q, J = 7.2 Hz, 1H), 7.15 (t, J =
8.4Hz, 1H), 7.21 – 7.35 (m, 5H), 7.69 (s, 1H), 7.83 (s, 1H), 7.91 (d, J = 5.6 Hz, 2H), 8.68 (d,
J = 5.2 Hz, 2H); 13C NMR (CDCl3, 100 MHz) δ 18.9, 31.1, 42.7, 48.0, 110.8, 112.2, 119.7,
120.5, 121.1, 127.7, 127.8, 128.1, 129.3, 134.3, 135.6, 141.1, 142.1, 147.7, 148.4, 149.1,
150.8, 161.4, 172.9; ESI-HRMS for C21H18N3O2 (M+H)+ calcd. 344.1399, found 344.1397,
Chiral purity (% ee >99, tR = 8.07 min).
(R)-2-phenyl-N-(2-(pyridine-4-yl)benzo[d]oxazol-5-yl)propionamide (72): 78%; white
solid; 1H NMR (CDCl3, 400 MHz) δ 1.59 (d, J = 7.2 Hz, 3H), 3.76 (q, J = 6.8 Hz, 1H), 7.21
– 7.29 (m, 1H), 7.32 – 7.41 (m, 6H), 7.90 (s, 1H), 7.97 (d, J = 4.8 Hz, 3H), 8.74 (s, 2H); 13C
NMR (CDCl3, 100 MHz) δ 18.9, 48.0, 110.8, 112.3, 119.8, 121.2, 127.7, 127.8, 129.2,
134.3, 135.6, 141.1, 142.1, 147.7, 150.7, 161.4, 172.9; ESI-HRMS for C21H18N3O2 (M+H)+
calcd. 344.1399, found 344.1393, Chiral purity (% ee 99, tR=11.29 min).
2-(2,3-dichlorophenylamino)-N-(2-(pyridine-4-yl)benzo[d]oxazol-5-yl)propionamide
(73): 71%; 1H NMR (CDCl3, 400 MHz) δ 1.72 (d, J = 6.8 Hz, 3H), 3.95 (dq, J1 = 7.2 Hz, J2
= 3.2 Hz, 1H), 4.79 (d, J = 2.8 Hz, 1H), 6.56 (d, J = 8.4 Hz, 1H), 6.96 (d, J = 8 Hz, 1H), 7.09
(t, J = 8 Hz, 1H), 7.46 (dd, J1 = 9.2 Hz, J2 = 2 Hz, 1H), 7.54 (d, J = 8.4 Hz, 1H), 8.06 (d, J =
4 Hz, 2H), 8.09 (d, J = 1.6 Hz, 1H), 8.56 (s, 1H), 8.8 (bs, 2H); 13C NMR (CDCl3, 100 MHz)
δ 20.0, 56.4, 110.8, 111.1, 112.4, 118.6, 119.6, 120.9, 121.2, 128.4, 133.5, 134.3, 134.7,
142.4, 144.1, 148.0, 150.9, 161.7, 171.7; ESI-HRMS for C21H17N4O2Cl2 (M+H)+ calcd.
427.0729 found 427.0724.
Preparation of (S)-N-methyl-2-(naphthalen-1-yloxy)-N-(2-(thiazol-5-
yl)benzo[d]oxazol-5-yl)propanamide (9, R1 = 5-thiazole, R2 = 1-naphthyl, R3=
(S)-Me, Y = O, X = H)—A solution of 63 (30 mg, 0.072 mmol) in 2 mL anhydrous THF
was added drop-wise to a suspension of sodium hydride (60% in mineral oil, 1.89 mg, 0.079
mmol) in anhydrous THF (3 mL) under a nitrogen atmosphere at 0 °C. The resulting mixture
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was stirred for 30 min at room temperature. The mixture was cooled to 0 °C and then MeI
(11.2 mg, 0.079 mmol) was added. The reaction mixture was stirred for 1 h at room
temperature. The reaction mixture was quenched with a few drops of water and extracted
with DCM. The organic layers were washed with brine, dried over anhydrous MgSO4,
filtered, and concentrated. The residue was purified by silica gel column chromatography
using ethyl acetate/n-hexane (40:60) to yield 9 (15 mg, 48%) as a white solid. 1H NMR
(CDCl3, 400 MHz) δ 1.62 (d, J = 6.4 Hz, 3H), 3.34 (s, 3H), 4.92 (q, J = 6.4 Hz, 1H), 6.49 (d,
J = 7.6 Hz, 1H), 7.03 (d, J = 8.4 Hz, 1H), 7.19 – 7.39 (m, 6H), 7.69 (d, J = 8 Hz, 1H), 7.90
(d, J = 8.4 Hz, 1H), 8.61 (s, 1H), 8.61 (s, 1H), 8.98 (s, 1H); 13C NMR (CDCl3, 100 MHz) δ
18.7, 39.0, 72.6, 105.9, 111.4, 119.0, 121.3, 122.3, 125.2, 125.29, 125.3, 125.5, 126.0,
126.5, 127.4, 134.7, 140.0, 142.6, 146.0, 149.7, 153.0, 156.9, 158.4, 171.3; ESI-HRMS for
C24H20N3O3S (M+H)+ calcd. 430.1225, found 430.1222, Chiral purity (% ee >99,
tR=12.2 min.
Preparation of (S)-2-((2,3-dichlorophenyl)amino)propionoic acid (11)—A
mixture of 10 (163 mg, 1.82 mmol), 2,3-dichloro iodobenzene (500 mg, 1.83 mmol),
Cs2CO3 (1.19 gr, 3.65 mmol), and CuI (69.7 mg, 0.36 mmol) in DMF (3 mL) under a
nitrogen atmosphere was heated at 90 °C for 48 h. The mixture was allowed to cool to room
temperature and then diluted with water and the pH was adjusted to 3 to 5 by the addition of
concentrated HCl. The mixture was extracted with DCM. The organic layers were washed
with brine, dried over anhydrous MgSO4, filtered, and concentrated. The residue was
purified by silica gel flash column chromatography using ethyl acetate/n-hexane (50:50) to
afforded 11 (240 mg, 57%) as a brown solid. 1H NMR (CDCl3, 400 MHz) δ 1.60 (d, J = 7.2
Hz, 3H), 4.17 (q, J = 7.2 Hz, 1H), 6.48 (d, J = 8 Hz, 1H), 6.85 (d, J = 8 Hz, 1H), 7.05 (t, J =
8.4 Hz, 1H).
Synthesis of (S)-2-(2,3-dichlorophenylamino)-N-(2-(pyridine-4-
yl)benzo[d]oxazol-5-yl) propionamide (15a)—The general procedure for 8 was
followed using 11 and 4 to produce 15a; 70%; brown solid; 1H NMR (CDCl3, 400 MHz) δ
1.72 (d, J = 6.8 Hz, 3H), 3.95 (dq, J1 = 7.2 Hz, J2 = 3.2 Hz, 1H), 4.79 (d, J = 2.8 Hz, 1H),
6.56 (d, J = 8.0 Hz, 1H), 6.96 (d, J = 8 Hz, 1H), 7.09 (t, J = 8 Hz, 1H), 7.47 (d, J = 8.4 Hz,
1H), 7.54 (d, J = 8.8 Hz, 1H), 8.08 (bd, 3H), 8.56 (s, 1H), 8.8 (bs, 2H); 13C NMR (CDCl3,
100 MHz) δ 19.9, 56.35, 110.7, 111.0, 112.5, 118.5, 119.7, 120.7, 121.2, 128.3, 133.5,
134.3, 134.8, 142.3, 144.1, 148.0, 150.8, 161.6, 171.9; ESI-HRMS for C21H17N4O2Cl2 (M
+H)+ calcd. 427.0729 found 427.0731, Chiral purity (% ee 90.5, tR = 20.4 min).
Preparation of (S)-methyl 2-(naphthalen-1-ylamino)propanoate (13)—Into a dry
round bottom flask equipped with a stir bar was added L-alanine methyl ester hydrochloride
(500 mg, 3.58 mmol), 1-naphthalene boronic acid (1000 mg, 5.81 mmol), Cu(OAc)2 (715
mg, 3.93 mmol), and 4 Å molecular sieves (1.34 g). The flask was sealed with a septum,
evacuated and back filled with oxygen. Triethylamine (0.92 mL) and dry DCM (30 mL)
were added. The reaction mixture was stirred at room temperature for 48 h. The reaction
mixture was quenched with 13 mL 2M NH3 in methanol. The volatiles were removed in
vacuo and the resulting crude oil was purified by silica gel flash chromatography using ethyl
acetate/n-hexane (10:90) to give 13 (280 mg, 34%) as a brown viscous oil. 1H NMR
(CDCl3, 400 MHz) δ 1.27 (t, J = 6.8 Hz, 3H), 1.61 (d, J = 6.8 H, 3H), 4.23 (q, J = 6.8 Hz,
2H), 4.31 (q, J = 6.4 Hz, 1H), 4.98 (bs, NH), 6.55 (d, J = 7.2 Hz, 1H), 7.27–7.35 (m, 2H),
7.45–7.49 (m, 2H), 7.78–7.81 (m, 1H), 7.90–7.93 (m, 1H).
Preparation of N-1-naphthalenyl L-alanine (14)—Ester 13 (40 mg, 0.174 mmol) was
dissolved in methanol (1mL) and 1M NaOH in aqueous solution (0.18 mmol, 1.1 eq) was
added drop-wise. The reaction mixture was stirred at room temperature for 12 h and then
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concentrated. The residue was dissolved in DCM and then extracted with 10% aqueous
Na2CO3 solution. The aqueous layer was acidified with 1M HCl. The precipitate was
collected and washed with DCM. The solid was purified by silica gel flash column
chromatography using ethyl acetate/n-hexane (40:70) to give 14 (25 mg, 67%) as a brown
solid. 1H NMR (CDCl3, 400 MHz) δ 1.60 (d, J = 6.8 Hz, 3H), 4.24 (q, J = 6.8 Hz, 1H), 6.49
(d, J1 = 6 Hz, J2 = 1.6 Hz, 1H), 7.18–7.25 (m, 2H), 7.39–7.41 (m, 2H), 7.72–7.81 (m, 2H).
Synthesis of (S)-2-(naphthalen-1-ylamino)-N-[2-(pyridin-4-yl)benzo[d]oxazol-5-
yl]propionamide (15b)—The general procedure for 8 was followed using 14 and 4 to
produce 15b (60%) as a brown solid. 1H NMR (CDCl3, 400 MHz) δ 1.79 (d, J = 6.8 Hz,
3H), 4.13 (q, J = 6.8 Hz, 1H), 4.69 (bs, 1H), 6.66 (d, J = 7.2 Hz, 1H), 7.56- 7.32 (m, 6H),
7.87 (d, J = 7.2 Hz, 1H), 7.95 (d, J = 8 Hz, 1H), 8.08 (bs, 3H), 8.79 (bs, 3H); 13C NMR
(CDCl3, 100 MHz) δ 20.2, 56.4, 106.9, 110.9, 112.4, 119.6, 12.7, 120.3, 121.1, 123.6,
125.7, 126.3, 126.6, 129.2, 134.3, 134.4, 135.0, 141.4, 142.3, 147.9, 150.9, 161.6, 172.4;
ESI-HRMS for C25H20N4O2 (M+H)+ calcd. 409.1586 found 409.1668, Chiral purity (% ee
97, tR = 36.4 min).
Preparation of 2-(2,3-dichlorophenyl)acetyl chloride (17)—2,3-
Dichlorophenylacetic acid (16, 500 mg, 2.43 mmol) was dissolved in thionyl chloride (4
mL) under a nitrogen atmosphere at 0 °C. The reaction mixture was heated at 90 °C for 2 h.
The excess thionyl chloride was removed in vacuo to afford 17 as a colorless liquid. This
material was used without further purification.
Preparation of (R)-4-benzyl-3-(2-(2,3-dichlorophenyl)acetyl)oxazolidin-2-one
(19)—(R)-4-benzyloxazolidin-2-one (18, 212.6 mg, 1.19 mmol) was dissolved in anhydrous
THF (8 mL) under a nitrogen atmosphere. The reaction mixture was cooled to −78 °C and
then a 2.5M solution of n-butyl lithium in hexanes (0.9 mL, 1.2 mmol) was added drop-
wise. After 1 h, 17 (492 mg, 2.4 mmol) was added. The reaction mixture was stirred for 15
min −78 °C. Then the reaction mixture was allowed to warm to 0 °C and stirred for 30 min.
The reaction mixture was then quenched with saturated aqueous NH4Cl solution. The
solvent was removed in vacuo, and then the mixture was extracted with DCM. The organic
layer was washed with brine, dried over anhydrous MgSO4, filtered, and concentrated. The
residue was purified by silica gel column chromatography using EtOAc/n-hexane (20:80) to
give 19 (350 mg, 80%) as a brown semi-solid. 1H NMR (CDCl3, 400 MHz) δ 2.77 (t, J = 12
Hz, 1H), 3.29 (d, J = 12.8 Hz, 1H), 4.23 (m,2H), 4.35 (d, J = 18.4 Hz, 1H), 4.47 (d, J = 18.4
Hz, 1H), 4.67 (m,1H), 7.16–7.30 (m, 7H), 7.40 (dd, J1 = 4 Hz, J2 = 2.4 Hz, 1H).
Preparation of (4R)-4-benzyl-3-(2-(2,3-dichlorophenyl)propanoyl)oxazolidin-2-
one (20)—To a solution of 19 (250 mg, 0.686 mmol) in anhydrous THF (10 mL) was
added sodium bis(trimethylsilyl)amide (0.61 mL, 0.617 mmol) at −78 °C under a nitrogen
atmosphere. After 1 h, methyl iodide (0.192 mL, 3 mmol) was slowly added. The reaction
mixture was stirred for 2 h at −78 °C and then allowed to warm to room temperature over 5
h. Reaction mixture was quenched with saturated aqueous NH4Cl. The mixture was diluted
with DCM. The organic layer was washed sequentially with water, saturated sodium sulfite
and brine. The organic phase was dried over anhydrous MgSO4, filtered and concentrated.
The residue was purified by silica gel chromatography eluting with a linear gradient ranging
from 5 to 20% ethyl acetate in n-hexane to provide 20 (200 mg, 77%) as a white foam. 1H
NMR (CDCl3, 400 MHz) δ 1.56 (d, J = 6.8 Hz, 3H), 2.79 (t, J = 12.0 Hz, 1H), 3.28 (d, J =
13.6 Hz, 1H), 4.09–4.16 (m, 2H), 4.66 (bs, 1H), 5.37 (q, J = 6.8 Hz,1 H), 7.19–7.37 (m, 8H).
Preparation of (R)-2-(2,3-dichlorophenyl)propionic acid (21)—To a solution of 20
(160 mg, 0.42 mmol) in THF (5 mL) and water at 0 °C, was added drop-wise a solution of
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lithium peroxide [prepared by adding 30% hydrogen peroxide (2.9mL, 2.10 mmol) to
lithium hydroxide (17.6 mg, 0.41 mmol) in water (0.679 mL)]. The reaction mixture was
stirred for 0 °C for 1 h, and then quenched with saturated aqueous Na2SO3 (1.28 mL). The
solvent was removed in vacuo. The residue was diluted with water and then extracted with
DCM (2 times). The aqueous layer was acidified with concentrated HCl and then extracted
with EtOAc (2 times). The EtOAc extracts were combined, washed with brine, dried over
anhydrous MgSO4, and concentrated. The residue was purified by silica gel column
chromatography using EtOAc/n-hexane (40:60) to afforded 21 (80 mg, 87%) as a white
solid. 1H NMR (CDCl3, 400 MHz) δ 1.51 (d, J = 7.2 Hz, 3H), 4.27 (q, J = 6.8 Hz, 1H),
7.16–7.24 (m, 2H), 7.37(d, J = 7.6 Hz, 1H).
Synthesis of (R)-2-(2,3-dichlorophenyl-N-(2-(pyridine-4-yl)benzo[d]oxazol-5-
yl)propionamide (22)—The general procedure for 8 using 21 and 4 yielded 22 as a white
solid (70%); 1H NMR (CDCl3, 400 MHz) δ 1.61 (d, J = 7.2 Hz, 3H), 4.31 (q, J = 6.8 Hz,
1H), 7.26 (t, J = 8 Hz, 1H), 7.42 – 7.54 (m, 4H), 7.98 (s, 1H), 8.05 (d, J = 4.4 Hz, 2H), 8.80
(d, J = 4 Hz, 2H); 13C NMR (CDCl3, 100 MHz) δ 17.8, 45.0, 111.0, 112.4, 119.7, 121.2,
126.8, 128.2, 129.7, 132.0, 133.7, 134.3, 135.4, 140.9, 142.3, 147.9, 150.8, 161.6, 171.3.
ESI-HRMS for C21H15Cl2N3O2 (M+H)+ calcd. 412.0620, found 412.0611, Chiral purity (%
ee 83, tR = 1.58 min).
Synthesis of 5-nitro-2-(pyridine-4-yl)-1H-benzo[d]imidazole (24)—4-Nitro-1,2-
phenylenediamine (23, 500 mg, 3.26 mmol) and 4-pyridine carboxaldehyde (419 mg, 3.91
mmol) were dissolved in DMF (10 mL). Disodium metabisulfite (742 mg, 3.91 mmol) was
added. The reaction mixture was heated at 120 °C for 24 h under a nitrogen atmosphere.
After allowing the mixture to cool to room temperature, volatiles were removed under
reduced pressure. The reaction mixture was then diluted with water and extracted from
DCM. The organic layer was dried on anhydrous MgSO4, filtered and concentrated. The
residue was purified by silica gel column chromatography using MeOH/CHCl3 (5:95) to
give 24 (480 mg, 61%) as a red solid. 1H NMR (CDCl3, 400 MHz) 8.7 (d, J = 9.2 Hz, 2H),
8.1 (d, J = 2.4 Hz, 1H), 8.03 (d, J = 8.2 Hz, 2H), 7.92 (dd, J1 = 8.0 Hz, J2 = 2.4 Hz, 1H), 7.82
(s, 1H).
Synthesis of 2-(pyridin-4-yl)-1H-benzo[d]imidazole-5-amine (25)—Substrate 24
was reduced by hydrogenation using the general procedure described for 4 to yield 25
(64%). 1H NMR (CDCl3, 400 MHz) 8.50 (d, J = 8.2 Hz, 2H), 7.44 (d, J = 8.2 Hz, 2H), 6.70
(dd, J1 = 8 Hz, J2 = 2Hz, 1H), 6.20–6.17 (dd, J1= 8 Hz, J2 = 2 Hz, 1H), 6.10 (s, 1H), 4.30 (s,
2H).
Preparation of 2-phenoxy-N-[2-pyridin-4-yl)-1H-benzo[d]imidazole-5-
yl]propionamide (26)—To a solution of 25 (50 mg, 0.237 mmol) in anhydrous THF (6
mL) was added 2-phenoxypropionyl chloride (52.5 mg, 0.284 mmol), TEA (36.2 mg, 0.355
mmol), 4-DMAP (2.89 mg, 0.023 mmol) at 0 °C. The reaction mixture was stirred for 30
min at room temperature and quenched with sodium bicarbonate solution. The reaction
mixture was diluted with DCM and washed with sodium bicarbonate solution followed by
brine solution. The organic layer was dried over anhydrous MgSO4, filtered and
concentrated. The residue was purified by silica gel column chromatography using MeOH/
CHCl3 (10:90) to furnish 26 (60 mg, 70%) as a brown solid. 1H NMR (CDCl3, 400 MHz) δ
1.68 (d, J = 6.8 Hz, 3H), 4.85 (q, J = 6.4 Hz, 1H), 6.95 – 7.05 (m, 4H), 7.26 – 7.32 (m, 2H),
7.52 (d, J = 8.4 Hz, 1H), 7.86 (d, J = 5.2 Hz, 2H), 8.08 (s, 1H), 8.57 (d, J = 5.2 Hz, 2H), 8.65
(s, 1H); 13C NMR (CDCl3, 100 MHz) δ 18.9, 75.5, 115.9, 117.72, 117.74, 120.8, 122.8,
130.1, 132.8, 137.6, 150.0, 150.3, 156.7, 171.5; ESI-HRMS for C21H16N3O3Cl2 (M+H)+
calcd. 428.0569 found 428.0578.
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Synthesis of (but-3-yn-2-yloxy)benzene (28)—Phenol (27, 422.9 mg, 4.49 mmol) and
but-3-yn-2-ol (300 mg, 4.28 mmol) were dissolved in anhydrous THF (10 mL) under a
nitrogen atmosphere at 0 °C. Then Ph3P (1.12 g, 4.26 mmol) was added portion-wise. The
reaction mixture was stirred for 10 min and then DEAD (894.6 mg, 5.14 mmol) was slowly
added. The resulting solution was heated at 70 °C for 20 h. The reaction mixture was
allowed to cool to room temperature and then water was added. The mixture was extracted
with DCM. The organic layer was dried over anhydrous MgSO4, filtered, and concentrated.
The residue was purified by silica gel flash chromatography using ethyl acetate/n-hexane
(5:95) providing 28 (450 mg, 69%) as a solid. 1H NMR (CDCl3, 400 MHz) δ 1.67 (d, J =
6.8 Hz, 3H), 2.47 (d, J = 2 Hz, 1H), 4.88 (q, J = 2 Hz, 1H), 6.97 – 7.03 (m, 3H), 7.28 – 7.32
(m, 2H).
Preparation of 5-azido-2-(thiazol-5-yl)benzo[d]oxazole (29)—A solution of 2-
(thiazol-5-yl)benzo[d]oxazol-5-amine (4, R1 = 5-thiazole, X = H, 50 mg, 0.23 mmol)
dissolved in 2 mL concentrated HCl:H2O (1:1) was cooled at −5 °C. Then a solution of
sodium nitrite (31.7 mg, 0.459 mmol) dissolved in water (15 mL) was slowly added. The
reaction mixture was stirred for 60 min and then neutralized with sodium acetate (37.7 mg,
0.459 mmol). Next, a solution of NaN3 (29.9 mg, 0.49 mmol) in water (0.5 mL) was slowly
added over a 30 min period maintaining a temperature between 0 – 5 °C. After additional
stirring for 30 min, the solution was allowed to warm to room temperature and then it was
extracted with ethyl acetate. The organic layer was dried over anhydrous MgSO4, filtered
and concentrated to yield 29 (50 mg, 89%) as a solid, which was used without further
purification.
Preparation of 5-(4-(1-phenoxyethyl)-1H-1,2,3-triazol-1-yl)-2-(thiazol-5-
yl)benzo[d]oxazole (30)—A mixture of 29 (37 mg, 0.15 mmol) and 28 (20 mg, 0.13
mmol) were dissolved in anhydrous acetonitrile (3 mL) under a nitrogen atmosphere. Then
DIPEA (53 mg, 0.40 mmol) was added and the mixture stirred at room temperature for 10
min. Next, CuI (51.7 mg, 0.27 mmol) was added portionwise and then the reaction mixture
was stirred for 40 min. The mixture was quenched with aqueous saturated NH4Cl, diluted
with water and extracted with DCM. The organic layer was dried over anhydrous MgSO4,
filtered and concentrated. The residue was purified by silica gel column chromatography
using ethyl acetate/n-hexane (50:50) to furnish 30 (43 mg, 84%) as a solid. 1H NMR
(CDCl3, 400 MHz) δ 1.77 (d, J = 6.4 Hz, 3H), 5.69 (q, J = 6.4 Hz, 1H), 6.90 – 6.97 (m, 3H),
7.22 – 7.24 (m, 2H), 7.66 (d, J = 8.8 Hz, 1H), 7.74 (dd, J1 = 8 Hz, J2 = 2 Hz, 1H), 7.90 (s,
1H), 7.99 (d, J = 2 Hz, 1H), 8.66 (s, 1H), 8.98 (s, 1H); 13C NMR (Pyridine-d5, 100 MHz) δ
22.1, 69.5, 112.3, 112.5, 116.6, 119.1, 121.7, 121.8, 125.8, 130.3, 135.3, 143.2, 146.9,
150.5, 151.1, 158.5, 159.0, 159.3; ESI-HRMS for C20H16N5O2S (M+H)+ calcd. 390.1025,
found 390.1031.
Preparation of N-(3-nitrophenyl)isonicotinamide (32)—The general procedure for 8
was followed using 3-nitroaniline (31) and isonicotinic acid to afforded 32 (68%) as a
yellow solid. 1H NMR (DMSO-d6, 400 MHz) δ 7.67 – 7.71 (m, 1H), 7.89 – 7.91 (m, 2H),
8.01 (dd, J1 = 8.4 Hz, J2 = 1.6Hz, 1H), 8.19 (dd, J1 = 8 Hz, J2= 1.6 Hz, 1H), 8.79–8.83 (m,
3H), 10.9 (NH, s, 1H).
Preparation of N-(3-aminophenyl)isonicotinamide (33)—N-(3-
nitrophenyl)isonicotinamide (32, 0.823 mmol) in 4 mL ethanol was heated to 70 °C. Then
SnCl2•H2O (4.2 mmol) was added in portions and refluxed until starting material
disappeared (~ 4 h). The reaction mixture was cooled and quenched with saturated sodium
bicarbonate solution, and extracted with ethyl acetate (3 × 10 mL). The organic layer was
washed with saturated sodium bicarbonate, brine, dried over anhydrous sodium sulfate,
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filtered and concentrated in vacuo to give a residue, which was used without further
purification.
Preparation of (S)-N-(3-(2-(2,3-
dichlorophenoxy)propanamido)phenyl)isonicotinamide (34)—The general
procedure for 8 was followed using 33 and 7 (R2 = 2,3-di-ClPh, Y = O, R3 = (S)-Me) to
afford 34 (63%) as a white solid. 1H NMR (CDCl3, 400 MHz) δ 1.67 (d, J = 6.8 Hz, 3H),
4.79 (q, J = 6.8 Hz, 1H), 6.84 – 6.88 (m, 1H), 7.15 – 7.23 (m, 3H), 7.31 (t, J = 8 Hz, 1H),
7.59 (d, J = 8 Hz, 1H), 7.68 (d, J = 4.4 Hz, 2H), 8.02 (s, 1H), 8.24 (s, 1H), 8.68 (s, 1H), 8.75
(s, 2H); 13C NMR (CDCl3, 100 MHz) δ 18.5, 77.0, 111.9, 113.3, 116.5, 117.0, 121.2, 123.0,
124.4, 128.0, 130.0, 134.5, 137.8, 138.3, 142.1, 150.8, 153.7, 164.0, 169.5; ESI-HRMS for
C21H18N3O3Cl2 (M+H)+ calcd. 430.0725 found 430.0725, Chiral purity (% ee >99,
tR=10.54).
Synthesis of N-(1-phenylethyl)2-pyridin-4-yl)benzo[d]oxazole-5-carboxamide
(36)—The general procedure for 8 was followed using 35 and α-methyl benzylamine to
give 36 (71%) as a white solid. 1H NMR (CDCl3, 400 MHz) δ 1.57 (d, J = 6.8 Hz, 3H), 5.29
(q, J = 6.8 Hz, 1H), 6.41 (d, J = 7.2 Hz, 1H), 7.19–7.25 (m, 1H), 7.29–7.36 (m, 4H), 7.58 (d,
J = 8.4 Hz, 1H), 7.85 (d, J = 8.4 Hz, 1H), 8.00 (d, J = 4.8 Hz, 2H), 8.13 (s, 1H), 8.77 (bs,
2H); 13C NMR (CDCl3, 100 MHz) δ 21.9, 49.7, 111.2, 119.6, 121.3, 126.0, 126.4, 127.8,
129.0, 132.4, 134.0, 142.0, 143.1, 151.0, 152.8, 162.1, 166.1; ESI-HRMS for C21H18N3O2
(M+H)+ calcd. 344.1399 found 344.1403.
Preparation of 6-nitro-2-(pyridin-4-yl)benzo[d]oxazole (38a)—The general
procedure for 3 was followed using 2-amino-5-nitrophenol (37) and 4-pyridyl
carboxaldehyde to give 38a (75%) as a yellow solid. 1H NMR (DMSO-d6, 400 MHz) 6.99–
7.05 (m, 1H), 8.13 (d, J= 5.2 Hz, 2H), 8.36 (d, J= 8.4 Hz, 1H), 8.89 (d, J = 7.4 Hz, 2H), 8.81
(s, 1H).
Preparation of 2-(pyridin-4-yl)benzo[d]oxazol-6-amine (39a)—The general
procedure for 4 was followed using 38a to obtained 39a (85%) as a yellow solid. 1H NMR
(DMSO-d6, 400 MHz) 5.61 (s, 2H), 6.66 (dd, J1 = 8 Hz, J2 = 2 Hz, 1H), 6.79 (d, J = 1.6 Hz,
1H), 7.44 (d, J = 8.8 Hz, 1H), 7.92 (d, J = 6 Hz, 2H), 8.71 (d, J = 6 Hz, 2H).
(S)-2-(2,3-dichlorophenoxy)-N-(2-(pyridin-4-yl)benzo[d]oxazol-6-
yl)propionamide (40a)—The general procedure for 8 was followed using 7 (R2 = 2,3-di-
ClPh, Y=O, R3=(S)-Me) and 39a to afford 40a (76%) as a white solid. 1H NMR (CDCl3,
400 MHz) δ 1.71 (d, J = 6.8 Hz, 3H), 4.85 (q, J = 6.6 Hz, 1H), 6.88 (dd, J1 = 7.2 Hz, J2 = 2.8
Hz, 1H), 7.12 – 7.18 (m, 2H), 7.24 (dd, J1 = 8.8 Hz, J2 = 2 Hz, 2H), 7.69 (d, J = 8.4 Hz, 1H),
7.99 (d, J = 5.6 Hz, 2H), 8.33 (s, 1H), 8.75 (d, J = 5.2 Hz, 2H), 8.91 (s, 1H); 13C NMR
(CDCl3, 100 MHz) δ 18.3, 76.7, 102.6, 113.0, 117.4, 120.5, 120.7, 122.6, 124.1, 127.8,
134.0, 134.2, 135.6, 138.3, 150.6, 151.1, 153.4, 160.8, 169.0; ESI-HRMS for
C21H16N3O3Cl2 (M+H)+ calcd. 428.0569, found 428.0567, Chiral purity (% ee >99,
tR=21.0).
(S)-2-(2,3-dichlorophenoxy)-N-(2-(thiazol-5-yl)benzo[d]oxazol-6-
yl)propionamide (40b)—A similar sequence of reactions that was used to prepare 40a
was also used to generate 40b as a white solid. 1H NMR (CDCl3, 400 MHz) δ 1.73 (d, J =
6.8 Hz, 3H), 4.88 (q, J = 6.4 Hz, 1H), 6.89 – 6.92 (m, 1H), 7.17 – 7.19 (m, 1H), 7.23- 7.26
(m, 2H), 7.66 (d, J = 8.8 Hz, 1H), 8.29 (s, 1H), 8.61 (s, 1H), 8.85 (s, 1H), 8.94(s, 1H); 13C
NMR (CDCl3, 100 MHz) δ 18.5, 76.9, 102.8, 113.2, 117.5, 120.1, 122.9, 124.3, 125.7,
128.1, 134.5, 135.4, 138.6, 142.4, 151.0, 153.6, 153.68, 156.2, 157.3, 169.2; ESI-HRMS for
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C19H14N3O3SCl2 (M+H)+ calcd. 434.0133, found 434.0139, Chiral purity (% ee >99, tR=
22.5).
Gene cloning, protein expression, purification and crystallization
The coding sequence of CpIMPDH enzyme was amplified by PCR from CpIMPDH-90-134-
pET28a plasmid10b using primers compatible with the ligation independent cloning vector
pMCSG7.21 The gene was cloned into pMCSG7 using a modified ligation-independent
cloning protocol.22 The recombinant construct produced fusion proteins with an N-terminal
His6-tag and a TEV protease recognition site (ENLYFQ↓S). The fusion protein was
expressed in an E. coli strain BL21(DE3) harboring pMAGIC plasmid encoding one rare E.
coli Arg tRNAs (covering codons AGG/AGA) in the presence of 100 μg/mL ampicillin and
30 μg/mL kanamycin. The cells were grown in enriched M9 media at 37 °C followed by an
overnight induction with 0.5 mM isopropyl-β-D-thiogalactoside (IPTG) at 18 °C. Cells were
harvested, resuspended in lysis buffer (50 mM HEPES pH 8.0, 500 mM KCl, 20 mM
imidazole, 10 mM 2-mercaptoethanol, 5% glycerol) and stored at –80° C.
CpIMPDH protein was purified according to a standard protocol.22 The protocol included
cell lysis by sonication, Ni2+-affinity chromatography on an ÄKTAxpress system (GE
Healthcare Life Sciences) followed by His6-tag cleavage using recombinant TEV protease23
and an additional Ni2+-affinity chromatography performed to remove the protease, the
uncut protein, and the affinity tag. In the final step, the protein was dialyzed against
crystallization buffer containing 20 mM HEPES pH 8.0, 150 mM KCl and 1 mM TCEP,
concentrated, flash frozen, and stored in liquid nitrogen. Crystallizations were set up with
the help of a Mosquito liquid dispenser (TTP LabTech) using the sitting-drop vapor-
diffusion method in 96-well CrystalQuick plates (Greiner Bio-One). For each condition, 0.4
μl protein solution and 0.4 μl crystallization formulation were mixed and equilibrated
against a 135 μl reservoir. Five crystallization screens were used. Crystals with IMP and 54
were obtained from a drop solution containing 6 mg/ml protein, 3 mM IMP and 0.5 mM 54.
Diffraction quality crystals appeared at 18 °C in 0.1 M succinic acid pH 7.0 and 15% (w/v)
PEG 3350. The crystals were mounted on CryoLoops (Hampton Research) and flash-cooled
in liquid nitrogen. The cryoprotectant consisted of 20% ethylene glycol.
Data collection and Structure determination
Diffraction data were collected at 100 K at the 19-ID beamline of the Structural Biology
Center at the Advanced Photon Source, Argonne National Laboratory.24 The single
wavelength data at 0.97923 Å (12.661406 keV) up to 2.1 Å were collected from a single
crystal of CpIMPDH complexed with IMP and 54. The crystal was exposed for 5 s per 1.0°
rotation of ω with the crystal to detector distance of 300 mm. The data were recorded on a
CCD detector Q315 from ADSC scanning 220°. The SBC-Collect program was used for all
data collection and visualization. Data collection strategy, integration, and scaling were
performed with the HKL3000 program package.25 A summary of the crystallographic data
can be found in Table S1.
The structure was determined by molecular replacement using chain A of the structure of
CpIMPDH (PDB ID 3FFS) as a search model with HKL3000 using the data to 3.0 Å.25 The
initial model contained 4 copies of the search model and there was extra electron density for
additional protein residues that were not part of the search model. The presence of IMP and
54 in the active site was apparent from the initial electron density map (Fo). Extensive
manual model building with coot26 and the subsequent refinement using phenix.refine27 was
performed against the full data set up to 2.1 Å until the structure converged to the R factor
(Rwork) of 0.162, and Rfree of 0.210 with the r.m.s. bond distances of 0.007 and the r.m.s.
bond angles of 1.104°. The asymmetric unit contains four protein chains, A, B, C and D
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comprised of residues 1–92 and 135–392 (chains A and C) and 2–92 and 135–392 (chains B
and D). The final model also includes four IMP molecules, four 54 molecules, five ethylene
glycol molecules and 486 ordered water molecules. Several residues including several N-
and C-terminal residues and those introduced as a cloning artifact (SNA)28 are missing due
to disorder. In addition, residues 312–325 of chain A, 309–235 of chain B, 311–325 of
chains C and D located on the surface of the tetramer were disordered and not modeled. The
stereochemistry of the structure was checked with PROCHECK29 and the Ramachandran
plot. Atomic coordinates and experimental structure factors of the structure have been
deposited in the PDB under the ID code 4IXH.
Inhibition of recombinant CpIMPDH
Recombinant CpIMPDH, purified from E. coli,12 was assessed by monitoring the production
of NADH by fluorescence at varying inhibitor concentrations (25 pM – 5 YM). IMPDH was
incubated with inhibitor for 5 min at room temperature prior to addition of substrates. The
following conditions were used: 50 mM Tris-HCl, pH 8.0, 100 mM KCl, 3 mM EDTA, 1
mM dithiothreitol (assay buffer) at 25 °C, 10 nM CpIMPDH, 300 μM NAD and 150 μM
IMP. To characterize the non-specific binding of inhibitors, assays were also carried out in
the presence of 0.05% BSA (fatty acid free). IC50 values were calculated for each inhibitor
according to Equation 1 using the SigmaPlot program (SPSS, Inc.):
(Eq. 1)
where υi is initial velocity in the presence of inhibitor (I) and υo is the initial velocity in the
absence of inhibitor. When the values of IC50 approach the concentration of enzyme, tight
binding treatment is used:
(Eq. 2)
Inhibition at each inhibitor concentration was measured in quadruplicate and averaged; this
value was used as υi. The IC50 values were determined three times; the average and standard
deviations are reported. Mechanism of inhibition was determined by fitting to equations for
competitive, noncompetitive/mixed and uncompetitive inhibition as previously described.16c
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Abbreviations
Cp Cryptosporidium parvum
CLint intrinsic clearance
BSA bovine serum albumin
Gorla et al. Page 20
J Med Chem. Author manuscript; available in PMC 2014 May 23.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
DCM dichloromethane
DEAD Diethylazodicarboxylate
DIPEA diisopropylethylamine
DMF N,N-dimethylformamide
EDCI•HCl 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
IMP inosine 5′-monophosphate
IMPDH inosine 5′-monophosphate dehydrogenase
hIMPDH human IMPDH
HTS high-throughput screening
MPA mycophenolic acid
MR molecular replacement
N.D not determined
r.m.s root-mean-square
TEA triethylamine
Toxo Toxoplasma
XMP xanthosine 5′-monophosphate
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Figure 1.
Optimized CpIMPDH inhibitors A110, C64, C97, P96 and D48 and CpIMPDH inhibitor 1
identified by HTS.
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Figure 2.
Inhibition of CpIMPDH by 68. Inhibitor concentrations: open squares, 630 nM; closed
squares, 380 nM; closed triangles, 130 nM; open triangles, 50 nM; open circles, 25 nM; no
inhibitor, closed circles.
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Figure 3.
The inhibitor binding site in IMPDH. (A) Structure of CpIMPDH in complex with IMP and
54 (violet-blue; PDB ID code 4IXH). (B) Structure of Chinese hamster IMPDH (gray; PDB
ID code)19 in complex with IMP and MPA. (C) Overlay of C. parvum and Chinese hamster
active sites. IMP, 54, MPA and residues interacting with the inhibitors are shown as sticks.
Numbers in parentheses in panel C indicate Chinese hamster labeling. Water molecules are
shown as red spheres and hydrogen bonding interactions are shown as blue dashed lines. An
apostrophe indicates a residue from the adjacent monomer.
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Figure 4.
Overlay of CpIMPDH structures with 54 (violet-blue; PDB ID code 4IXH) and C64 (PDB
ID code 3KHJ).10b IMP, 54, C64 and the interaction residues are shown as sticks. A water
molecule is shown as a red sphere and hydrogen bonding interactions are shown as blue
dashed lines. An apostrophe denotes a residue from the adjacent monomer.
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Scheme 1.
General procedure for the synthesis of benzoxazole derivatives.
Reagents and conditions: (a) R1-CHO, O2, DarcoKB, xylene, 120 °C, 6 h, 70–80% (b) H2 (1
atm), 10% Pd-C, EtOAc, 6 h, 80–86% (c) R3CHBrCOOR4, K2CO3, DMF, rt, 5 h, 85–92%
when Y = O (or 70 °C, 3 h, 36% when Y = NH) (d) (R)- or (S)- R3CH(OH)COOR4, 0 °C,
PPh3, 10 min, DEAD, rt, 12 h, 75–84% (e) 3 M NaOH, THF:H2O (2:1), 80 °C, 3 h, 85–95%
(f) 3N HCl, THF, 70 °C, 6 h, 60–70% (g) EDCI•HCl, DMF, 0 °C - rt, 12 h, 63–79% (h)
MeI, NaH, THF, 0 °C - rt, 1.5 h, 48%.
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Scheme 2.
General procedure for the synthesis of enantiomerically pure secondary amines of 5-
benzoxazoles.
Reagents and conditions: (a) 2,3-di-ClPhI, Cs2CO3, CuI, DMF, 90 °C, 48 h, 57% (b) L-
alanine methyl ester hydrochloride, Cu(OAc)2, DCM, TEA, oxygen, 4Å molecular sieves,
rt, 48 h, 34% (c) 1 M NaOH, MeOH, rt, 12 h, 67% (d) 4, EDCI•HCl, DMF, 0 °C - rt, 12 h,
60–70%.
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Scheme 3.
Synthesis of a 2-phenylpropionamide benzoxazole derivative.
Reagents and conditions: (a) SOCl2, 90 °C, 2 h (b) 18, n-BuLi (2.5 M), THF, −78 °C to 0
°C, 1 h, 80% (c) (i) NaN(TMS)2 in THF, −78 °C, 1 h (ii) MeI, THF, −78 °C, 2 h (iii) rt, 5 h,
77% (d) Li2O2, THF, H2O, 0 °C, 1 h, 87% (e) 4 (R1 = 4-Py, X = H), EDCI•HCl, DMF, 0 °C
- rt, 12 h, 70%.
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Scheme 4.
Synthesis of a benzimidazole derivative.
Reagents and conditions: (a) 4-PyCHO, Na2S2O5, DMF, 120 °C, 24 h, 61% (b) H2 (1 atm),
10% Pd-C, MeOH, rt, 6 h, 64% (c) PhOCH(CH3)COCl, TEA, cat. 4-DMAP, THF, 0 °C – rt,
30 min, 70%. A benzimidazole analogue of 1 was prepared using the method outlined in
Scheme 4. 6-Nitro-2-(pyridin-4-yl)-1H-benzo[d]imidazole (24) was prepared by
condensation of 4-pyridine carboxaldehyde with 4-nitro-1,2-phenylenediamine (23) in the
presence of the oxidizing agent sodium metabisulphite.10d The product was reduced in the
presence of hydrogen (1 atm) and 10% Pd-C to give 25, which was then coupled with 2-
(phenoxy)propionoyl chloride in the presence of triethylamine and catalytic DMAP to give
26.
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Scheme 5.
Synthesis of a 1,2,3-triazole derivative.
Reagents and conditions: (a) CH3CH(OH)C CH, PPh3, 0 °C, 10 min then DEAD, THF, 70
°C, 20 h, 69% (b) NaNO2, HCl, H2O, NaN3, -5 °C – 0 °C, 1.5 h, 89% (c) CH3CN, DIPEA,
CuI, rt, 50 min, 84%.
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Scheme 6.
Synthesis of an 1,3-diamide derivative.
Reagents and conditions: (a) 4-PyCO2H, EDCI•HCl, DCM, 0 °C - rt, 12 h, 68% (b)
SnCl2•H2O, EtOH, 70 °C, 4 h, 62% (c) (S)- 2,3-di-Cl-PhOCH(CH3)COOH, EDCI•HCl,
DCM, 0 °C - rt, 12 h, 63%.
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Scheme 7.
Synthesis of amide derivative 36.
Reagents and conditions: (a) α-methyl benzyl amine, EDCI•HCl, DMF, 0 °C - rt, 12 h, 71%.
An analogue of 22 in which the amide group is inverted was prepared using the method
outlined in Scheme 7. Amide 36 was generated by coupling 2-(pyridin-4-
yl)benzo[d]oxazole-5-carboxylic acid (35) and α-methylbenzylamine in the presence of
EDCI•HCl.
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Scheme 8.
General procedure for the synthesis of 6-substituted benzoxazole derivatives.
Reagents and conditions: (a) RCHO, O2, DarcoKB, xylene, 120 °C, 6 h, 75% (b) H2 (1 atm),
10% Pd-C, EtOAc, rt, 6 h, 85% (c) (S)-2,3-di-Cl-PhOCH(CH3)COOH, EDCI•HCl, DMF, 0
°C - rt, 12 h, 76%.
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Table 1
SAR of phenyl ring of 1 for CpIMPDH inhibition.
ID R1
IC50 (nM)
(−) BSA (+) BSA
1 2,4-di-ClPh 44 ± 8 120 ± 10
41 2-ClPh 19 ± 2 50 ± 10
42 4-ClPh 105 ± 17 118 ± 3
43 Ph 40 ± 5 50 ± 20
44 4-OMePh 28 ± 2 34 ± 5
45 3-ClPh 20 ± 7 32 ± 8
46 2,3-di-ClPh 3 ± 1 11 ± 1
47 2,6-di-ClPh >5000* n.d
48 1-naphthyl 9 ± 3 14 ± 6
49 1-(4-Cl-naphthyl) 27 ± 1 53 ± 9
*One determination, n.d. = not determined.
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Table 2
SAR of amide α-position of 1 for CpIMPDH inhibition.
ID X R1
IC50 (nM)
(−) BSA (+) BSA
50 CH2 2,4-di-ClPh >5000* n.d
51 CMe2 4-ClPh >5000* n.d
52 CH-i-Pr 1-naphthyl 24 ± 2 57 ± 5
53 (R)-CHMe 1-naphthyl 400 ± 70 380 ± 60
54 (S)-CHMe 1-naphthyl 6.1 ± 0.5 8 ± 3
55 (S)-CHMe 2,3-di-ClPh 1.2 ± 0.2 3.5 ± 0.7
56 (S)-CHMe 2-Cl,3-CF3Ph 9 ± 1 52 ± 5
57 (S)-CHMe 2-Cl,3-NO2Ph 2.3 ± 0.9 6 ± 4
58 (S)-CHMe 2,3-di-OMePh 50 ± 10 60 ± 20
*One determination, n.d. = not determined.
J Med Chem. Author manuscript; available in PMC 2014 May 23.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Gorla et al. Page 38
Ta
bl
e 
3
SA
R 
of
 th
e 
py
rid
in
e 
rin
g 
of
 1
 
fo
r C
pI
M
PD
H
 in
hi
bi
tio
n.
ID
X
R
1
R
2
IC
50
 
(n
M
)
(−
) B
SA
(+
) B
SA
59
M
e
2,
4-
di
-C
lP
h
Ph
>
50
00
*
n
.d
60
M
e
2,
4-
di
-C
lP
h
3-
Py
15
0 
± 
20
60
0 
± 
20
0
61
M
e
2,
4-
di
-C
lP
h
2-
Py
21
0 
± 
20
80
0 
± 
20
0
62
(S
)-M
e
2,
3-
di
-C
lP
h
1.
4 
± 
0.
3
2.
3 
± 
0.
4
63
(S
)-M
e
1-
na
ph
th
yl
2.
7 
± 
0.
7
4.
0 
± 
0.
9
64
M
e
1-
(4-
Cl
-na
ph
thy
l)
28
 ±
 6
70
 ±
 1
0
65
(S
)-M
e
2,
3-
di
-C
lP
h
17
 ±
 6
30
 ±
 1
0
J Med Chem. Author manuscript; available in PMC 2014 May 23.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Gorla et al. Page 39
ID
X
R
1
R
2
IC
50
 
(n
M
)
(−
) B
SA
(+
) B
SA
66
(S
)-M
e
1-
na
ph
th
yl
26
 ±
 5
50
 ±
 5
67
M
e
1-
na
ph
th
yl
>
50
00
*
n
.d
*
O
ne
 d
et
er
m
in
at
io
n,
 n
.d
. =
 n
ot
 d
et
er
m
in
ed
.
J Med Chem. Author manuscript; available in PMC 2014 May 23.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Gorla et al. Page 40
Table 4
Other miscellaneous changes to explore the SAR of 1 for CpIMPDH inhibition.
ID Structure
IC50 (nM)
(−) BSA (+) BSA
30 >5000* n.d.
9 >5000* n.d.
36 >5000* n.d.
40a 0.6 ± 0.5 4 ± 2
40b 7 ± 1 60 ± 20
68 240 ± 90 600 ± 300
26 >5000* n.d.
34 >5000* n.d.
*One determination, n.d. = not determined.
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Table 5
SAR of benzyl amide derivatives of 1 for CpIMPDH inhibition.
ID X R1
IC50 (nM)
(-) BSA (+) BSA
69 Me CH2Ph > 5000 n.d.
70 Me Ph 120 ± 20 130 ± 30
71 (S)-Me Ph >5000* n.d.
72 (R)-Me Ph 22.3 ± 5.9 28.0 ± 3.5
22 (R)-Me 2,3-di-ClPh 60 ± 3
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Table 6
SAR of secondary amine derivatives of 1 for CpIMPDH inhibition.
ID X R1
IC50 (nM)
(−) BSA (+) BSA
73 Me 2,3-di-ClPh 2 ± 1 1.8 ± 0.5
15a (S)- Me 2,3-di-ClPh 0.5 ± 0.1 1.1 ± 0.1
15b (S)- Me 1-naphthyl 14 ± 6 15 ± 3
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Table 7
Mechanism of inhibition of CpIMPDH by selected compounds.
Cmpd Substrate Mechanism Kis (nM)
1 IMP NC 58 ± 5
NAD C 33 ± 8
63a IMP NC 1.6 ± 0.7
NAD C 0.9 ± 0.3
68 IMP NC 210 ± 10
NAD C 150 ± 30
72 IMP NC 100 ± 20
NAD C 40 ± 10
aQ26 was analyzed using tight binding treatment;
NC: noncompetitive; C: competitive.
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Table 9
Antiparasitic activity of select compounds. Assays as described in Methods18. Unless otherwise stated all
values are the average of three independent determinations.
Compound EC50 (μM) Selectivitya
Toxo/WT Toxo/CpIMPDH
1 1.3 ± 0.1 b 0.65 ± 0.03 b 2
26 9 ± 3 9 ± 3 1
40a 3 ± 1 0.02 ± 0.02 150
41 3.0 ± 1.0 0.9 ± 0.4 3
43 7 ± 4 4 ± 2 2
44 >25 0.5 ± 0.2 >50
45 1.1 ± 0.4 0.5 ± 0.1 2
46 8 ± 2 0.22 ± 0.04 40
48 2.4 ± 0.3 0.20 ± 0.09 b 34
54 2.2 ± 0.6 0.4 ± 0.3 5
55 5 ± 2 0.3 ± 0.1 16
56 1.7 ± 0.6 0.8 ± 0.4 2
57 3 ± 1 0.19 ± 0.03 14
58 21 ± 6 0.7 ± 0.1 30
62 3.3 ± 0.5 0.2 ± 0.01 15
63 3.2 ± 0.8 0.30 ± 0.3 11
64 5 ± 4 2 ± 2 3
65 2.2 ± 0.8 0.3 ± 0.1 7
66 1.7 ± 0.7 1.0 ± 0.1 1.7
70 5 ± 3 2.5 ± 0.2 1.9
72 2.1 ± 0.5 0.4 ± 0.1 5
73 4 ± 2 0.02 ± 0.02 200
aSelectivity is the ratio of EC50 Toxo/CpIMPDH to EC50 Toxo/WT.
b
Two determinations.
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